

INDEX

- 1,4,5-IP₃, 41, 171
 1,4,5-triphosphate (IP₃), 93, 246
 6B4, 351
 14-3-3ξ, 23, 152
 17β-estradiol (17β-E₂, 100nM), 61, 209
- α-actinin, 4, 129
- α granules, 1, 93, 125, 247
 contents release by, 15, 149
 defects
 α-Storage Pool Deficiency, 61–62, 209
 Jacobsen Syndrome (JS), 63, 211
 Medich platelet disorder, 63, 211
 Paris Trousseau Syndrome (PTS), 63, 211
 Quebec platelet disorder (QPD), 62, 210
 White Platelet Syndrome (WPS), 63, 211
 and inflammation, 326
 sCD40L and, 56, 204
- α,δ-storage pool deficiency, 63, 211
- α₂ integrin (GPIa), 29, 163
- α_{2A}-adrenergic receptor, 66, 214
- α₂-adrenergic receptors, 58, 206
- α₂β₁ integrin, 28–29, 163
 platelet receptors for, 341
 polymorphisms, 29, 163
 GPIa (α₂ integrin), 29, 163
 signaling, 29, 162
 structure, 28, 162
- α-granule proteins, 85, 235
- αIIb β₃ blockers
 and bleeding, 81, 230
 and iatrogenic platelet disorders, 81, 229
 laboratory monitoring, 81, 230
- αIIbβ₃, 85, 234
- αIIbβ₃ antagonists
 monitoring, 392
 variation in response to, 392
- αIIbβ₃ integrin, 9, 161
 affinity regulation, 26, 157
 clinical relevance and future directions, 27, 161
 epitopes location for conformation-dependent mAbs, 26, 159
 ligand-binding site location, 26, 158
 polymorphisms, 11, 161
 structure, 25–26, 157
- α-Storage Pool Deficiency, 61, 209
 A156 V mutation, 55, 202
- abciximab, 2, 81, 87, 125, 229, 243, 345, 392, 419
 for arterial thrombosis treatment and prevention, 112, 266
 bleeding complications, 379
 for patients with STEMI, 428
 vs. placebo, 428
 pharmacokinetics, 419
 recanalization with, 447
 recommended for PCI treatment, 422
 to reduce reocclusion after angioplasty, 466
 and surgery, 86, 237
 thrombocytopenia from, 380
- Abciximab Before Direct Angioplasty and Stenting in MI
 Regarding Acute and Long-Term Follow-Up (ADMIRAL)
 trial, 428
- Abciximab Emergent Stroke Treatment Trial (AbESTT), 447
- Abciximab Emergent Stroke Treatment Trial-II (AbESTT-II),
 447
- abdominal vein thrombosis (AVT), 47, 190
- ABO blood group
 compatibility, 93, 247
 for infant and platelet donor, 93, 246
- ACCP Consensus Conference on Antithrombotic Therapy, 465
- ACCP Consensus Conference, recommendation on aspirin
 use, 464
- acenocoumarol
 and uncontrolled bleeding, 23, 152
- acetylsalicylic acid (ASA). *See* aspirin
- acid phosphatases
 in lysosomes, 3, 125–127
- acidosis, in trauma patients, and platelet dysfunction, 98, 252
- acquired coagulation factor deficiency, 23, 151
- acquired von Willebrand syndrome (AVWS), 53, 191
- actin, 9, 137
 assembly, 15, 149
 actin binding protein, 24, 152
 actin cytoskeleton, 4, 128
 and G_qG₁₃, 43, 172
- actin filaments
 distribution, 11, 139
- actin toxins, 11, 139
- activated partial thromboplastin time (APTT),
 21, 150

Index

- activated platelets
 - and arterial thrombosis, 109, 262
 - α IIb β 3 in, 26, 157
 - complex formation with monocytes, 81, 231
 - ex vivo flow cytometry for assessing, 8, 135
 - flow cytometry detection, 8, 135
 - inflammatory molecules produced by, 107, 270
 - structure, 13–15, 150
 - granule secretion, 15, 149
 - shape change, 14, 147
- active bleeding, therapeutic platelet transfusions, 99, 251–254
- Acute Catheterization and Urgent Intervention Strategy (ACUITY) trial, 425, 427
- acute coronary syndrome (ACS), 3, 126, 279
 - clopidogrel for patients with, 414
 - plaque rupture in, 68, 216
- acute lymphoblastic leukemia
 - abnormal platelet function in, 85, 234
- acute myelogenous leukemia
 - δ -SPD and development, 60, 208
- ADAMTS13
 - deficiency, 175
 - inherited deficiency, 165
- aducan, 5, 130
- adenosine, 326
- adenosine 5'-diphosphate (ADP), 40, 60, 84, 175, 207, 234
 - in dense granules, 2, 93, 126, 248
 - enzymatic degradation, 92, 244
 - monitoring stimulated responses, 397
 - and platelet activation, 93, 246
 - and platelet aggregation, 1–5, 129, 131
 - and platelet function, 97, 251
 - platelet receptors for, 341
 - receptor antagonists, 343–345, 429
 - release from platelet granules, 282
 - succinate and, 64, 212
- adenosine 5'-triphosphate (ATP), 60, 207
 - in dense granules, 2, 126
 - increased, in cystic fibrosis, 332
 - measurement of secretion, 11, 140
 - PGE₂ and, 62, 210
 - and proplatelet elongation, 10, 139
- adenosine receptors, 343
- adenylate cyclase, 343
- adhesion molecules
 - from activated platelets, 106, 255
- adhesion proteins
 - hereditary defects, 67, 215
 - as platelet-derived mediators, 108, 255
 - platelet receptor abnormalities, 57, 204
 - α_2 -adrenergic receptors, 58, 206
 - Glanzmann's thrombasthenia (GT), 203
 - GP1a/IIa (α_2/β_1) abnormalities, 56, 204
 - GPVI abnormalities, 57, 204
 - P2Y₁ receptor abnormalities, 57, 204
 - thromboxane A₂ receptor defects, 58, 205
 - von Willebrand disease (VWD), 56, 202
- adiponectin, 61, 208
- adipose tissue
 - and leptin, 60, 208
- ADP. *See* adenosine 5'-diphosphate (ADP)
- ADP-receptor (P2Y₁₂) antagonists, 115, 269
- afibrinogenemia, 68, 215
- aggregometer
 - for quantifying platelet function in whole blood sample, 7, 132
- AGI-1067, 302
- aging, and atherosclerosis, 293
- air travel-related, venous thromboembolism (VTE)
 - preventing, 478
- airway obstruction, PDHRF and, 326
- airway remodeling
 - chronic inflammation in bronchial asthma in, 330
- Akt
 - and Gas6 activities, 54, 194
- Akt1, 43, 175
- Akt2, 43, 172–175
- Alberio, L., 86, 236
- albinism
 - oculocutaneous, 25, 208
- alcohol abuse, 21, 150
- allergen, platelet response to, 331
- allergic asthma, 330
- allergic dermatitis, 333
- allergic inflammation
 - platelet chemotaxis in, 328
- alloimmune thrombocytopenia (AIT)
 - fetal and neonatal, 43, 169–172
 - clinical presentation, 41, 170
 - diagnosis, 41, 171
 - intracranial haemorrhage (ICH), 41, 171
 - long-term effects of antenatal management, 43, 175
 - management strategies, 43, 174
 - overall approach to therapy, 43, 173
 - pathogenesis, 41, 169
 - predictors of disease, 41, 171
 - screening programs, 43, 172–175
- alloimmune thrombocytopenia (AIT), 24, 155
- alloimmunized platelet refractoriness, 93, 247
 - management, 94, 248
 - prevention, 93, 247
- alpha-thrombin-induced serotonin
 - LDL and, 57, 204
- American Association of Blood Banks, 87, 243
- American College of Cardiology/American Heart Association
 - guidelines for NSTEMI ACS treatment, 415
 - PCI guidelines, 398
- American College of Chest Physicians, 477
- American Heart Association (AHA) Guidelines for Primary
 - Prevention of Cardiovascular Disease and Stroke, 409
- AMG531
 - for refractory ITP, 29, 163
- amine-polystyrene particles, 63, 212
- amino acids
 - residues for ligand binding, 26, 158
- aminoxidases, 109, 265

- aminophospholipid translocase, 83, 233
- Amotosalen HCl
adding to platelet transfusions, 244
- anagrelide, 353
- Anand, S.S., 375
- Ancylostoma caninum*, 374
- Andonegui, G., 63, 211
- Andre, P., 81, 230
- anemia
in childhood, 29, 163
from erythropoietin deficiency, 83, 232
- angiogenesis
platelet regulation of, 251, 308
regulators of, 2, 125
- angioplasty, reocclusion after, abciximab to reduce rate, 466
- angiopoietin-1, 2, 313, 315
- angiotensin converting enzyme (ACE), 99, 251–254
- angiotensin-converting enzyme inhibitors (ACEI)
interaction between aspirin and, 380
- ankle brachial index (ABI), 458
- ankle pressure index, 458
- antibiotics
prophylactic after splenectomy in children, 30, 165
- antibodies
to Human Leukocyte Antigens (HLA) Class I, 93, 247
loss over time, 95, 248
- anticoagulant factors, 108, 261
- anticoagulants
for arterial thrombosis treatment and prevention, 112, 267
for atrial fibrillation with other risk factors, 451
in CHF management, 115, 268
haemorrhagic complications vs. antiplatelet therapies, 378
intracranial haemorrhage (ICH) and, 378
for myocardial infarction prevention, 109, 265
oral therapy, 373
vs. antiplatelet therapies, 376
in CAD treatment, 374
overtreatment with, and haematomas, 15, 149
and platelet count, 1, 124
role in preventing stroke in atrial fibrillation, 376
for systolic dysfunction, 115, 269
- anti-D
for ITP, 159
in children, 30, 164
limitations, 27, 160
- antigen, binding to IgE, 328
- anti-LIBS (ligand-induced binding site) antibodies, 26, 158
- antiphospholipid antibodies (APLA), 156
- antiphospholipid syndrome, 109, 264
- antiplatelet therapies, 407
ADP receptor antagonists, 343–345
and arterial bypass surgery, 464–465
aspirin, 342, 370
in atrial fibrillation, 411
clinical efficacy in cardiology, 407
dose, 409
mechanism of action, 407
pharmacokinetics, 407
resistance, 411
dipyridamole, 346
experimental
collagen receptors, 351
COX inhibitors, 351
GPIIb-vWF interaction, 350
P-selectin, 351
serotonin, 351
future research, 381, 429
glycoprotein IIb/IIIa inhibitors, 261, 418–429
hemorrhagic complications vs. anticoagulants, 378
and hemostatic abnormalities, 99, 254
impact on limb ischemia, 462
irreversible, 345
monitoring, 392
future research, 400
laboratory, 386
summary and future of, 399
nonhemorrhagic complications, 379
vs. oral anticoagulants
in atrial fibrillation, 376–378
for heart failure treatment, 376
in percutaneous endovascular revascularization, 465
pharmacogenomic factors in resistance to, 353
as potential cancer growth inhibitors, 312
to prevent arterial thrombosis, 471
for preventing cardiovascular events, 460
resistance, 155
in stroke prevention, 438
for stroke treatment and secondary prevention
aspirin, 280
clopidogrel, 323
dipyridamole, 445
future research, 453
glycoprotein IIb/IIIa receptor antagonists, 329
ticlopidine, 444
warfarin, 448
thienopyridines, 412–418
antiplatelet effects, 412
See also clopidogrel; ticlopidine
for thrombosis prophylaxis, 109, 265
thromboxane pathway inhibitors, 347
and warfarin, 374
- Antiplatelet Trialists' Collaboration, 460, 462, 464, 473, 479
- antithrombin, 109, 265
- antithrombin III (ATIII)
levels in diabetes mellitus-type II, 286
- antithrombotic therapy
 $\alpha_{IIb}\beta_3$ integrin as target of, 27, 161
for atrial fibrillation, 381
with direct thrombin inhibitors (DTI), 372
future research, 357
for peripheral vascular surgery, 465
tissue factor and factor VIIa as targets, 374
with pentasaccharides and factor Xa inhibitors, 370–372
with unfractionated heparin and Low Molecular Weight Heparins, 125
- Antithrombotic Trialists' Collaboration, 309, 410, 461, 471

Index

- anuria
in HUS, 45, 176
- aortic stenosis (AS) BK
AVWS and, 85, 235
- apheresis platelets, 86, 242
- apixaban, 373
- APLA. *See* antiphospholipid antibodies (APLA)
- aplastic anemia
from clopidogrel, 380
from ticlopidine, 380
- ApoE^{-/-} mouse, 293
for investigating platelet adhesion in atherosclerotic lesion development, 295
- apoptosis, 13, 142
- apoptosis inhibitory proteins, 13, 147
- aprotinin, 99, 253, 350
- arachidonate
Tx₂ from, 46, 186
- arachidonate metabolites, 59–60, 207
- arachidonic acid (AA), 5, 79, 84, 107, 131, 228, 234, 255, 327
impaired liberation from membrane phospholipids, 64, 212
metabolism, 97, 251
in diabetic patients, 285
and platelet aggregation, 4, 129
in prostaglandin synthesis, 342
- arachidonic acid metabolism, 62, 210
- arachidonic acid-induced platelet thromboembolism, 67, 215
- Arg/Gln substitution, 27, 160
- argatroban, 350, 372
- Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial, 371
- Arp 2/3 complex of proteins, 15, 149
- arterial bypass surgery
and antiplatelet therapies, 464–465
- arterial circulation
walking distance and impaired, 463
- arterial stents
combination clopidogrel/aspirin therapy after, 444
ticlopidine after, 445
- arterial thrombi, 108, 261
and activated platelets, 109, 262
antiplatelet therapies, 367, 471
clinical presentation, 113, 261–267
consequences of, 108, 261
future research, 289
leptin and, 66, 213
risk factors for, 109, 262
treatment and prevention, 113, 265–267
anticoagulation, 112, 267
aspirin, 109, 265, 367
cilostazol, 111, 266
dipyridamole, 111, 266
glycoprotein IIb/IIIa inhibitors, 112, 266
thienopyridines, 110, 265
- arterial wall tissue factor
role of, 81, 229
- atherosclerosis
mouse model, 67, 215
- aryl sulfatase
in lysosomes, 3, 125–127
- ASA (acetylsalicylic acid). *See* aspirin
- ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) trial, 396
- Ashcoff, K., 12
- ASPECT (Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis), 112, 267
- aspirin, 342
and allergic asthmatics, 332
anticancer activity, clinical trials, 316
anti-inflammatory effects, 115, 268
for arterial thrombosis treatment and prevention, 109, 265, 367
for atrial fibrillation, 411, 439
or warfarin vs. placebo, 450
benefits of, 342
and bleeding time, 3, 128
for carotid artery stenosis, 438
clinical efficacy in cardiology, 407
primary prevention, 156
secondary prevention in CAD, 409
clopidogrel in combination with, 80, 229, 378, 442
vs. clopidogrel, 414
for PAD, 461
for coronary artery disease, 374
dipyridamole use with, 347
dose, 409
effect on thromboprophylaxis, 309
effectiveness of, 352
gastric bleeding from, 342
guidelines for cessation prior to surgery, 86, 236
and iatrogenic platelet disorders, 227
impact on platelets, 86, 236
interaction with angiotensin-converting enzyme inhibitors (ACEI), 380
laboratory monitoring, 79, 228
low-dose
for cardiovascular disease, 462
vs. high-dose, after angioplasty, 466
measuring platelet responses to, 390
mechanism of action, 407
monitoring, 393
nonhemorrhagic complications, 379
NSAID drug interaction with, 353
for peripheral arterial disease, 460
pharmacokinetics, 407
vs. placebo, for preventing stroke, 452
as platelet inhibitor, 87, 243, 288, 472
and postoperative bleeding, 476
and priming activity, 70
resistance, 4, 79, 129, 228, 342, 394, 411
identifying with PFA-100, 395
role in thromboprophylaxis, 310
side effects, 378
and stroke
optimal dose for secondary stroke prevention, 441
prevention, 438

- risk, 408
- treatment and secondary prevention, 280
- with thienopyridines for peripheral endovascular procedures, 466
- and thrombopoietin, 58, 207
- thromboxane A₂ (TxA₂) measurement for monitoring therapy, 391
- ticlopidine with, 413
- variation in response to, 392
- and warfarin, 374
 - for noncardioembolic stroke, 448
 - for PAD, 461
- ximelagatran and, 373
- aspirin effect, 69, 226
- aspirin therapy
 - in low-risk ET, 54, 194
- assassin bug, 351
- Assessment of best Loading Dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis (ALBION) study, 416
- Assessment of Safety and Efficacy of New Thrombolytic Regimen (ASSENT)-3 trial, 428
- asthma, 159
 - clinical studies, 330
 - experimental animal studies, 329
 - serotonin and, 325
- atherosclerosis, 99, 251–254, 279, 293
 - assessment of burden and risk, 293
 - biological markers to predict presence, 293
 - clinical manifestations, 301
 - future research, 302
 - and inflammatory cells accumulation, 294
 - hypochlorite-modified proteins in plaques, 57, 204
 - and peripheral arterial disease (PAD), 458
 - platelet adhesion
 - and lesion formation initiation, 295
 - transition from loose to firm, 296
 - risk factors for, 279
 - second-hand smoke and, 22, 264
- atopic dermatitis, 333
- atorvastatin
 - clopidogrel interaction with, 353, 417
- ATP. *See also* adenosine 5'-triphosphate (ATP)
- atrial fibrillation, 114, 267
 - antiplatelet therapies vs. oral anticoagulants, 376–378
 - antithrombotic therapy for, 115, 269
 - aspirin for, 411, 439
 - and cerebral ischemic events, 288
 - clopidogrel in, 418
 - and other risk factors
 - anticoagulants for, 451
 - pathogenesis of thromboembolic events in, 376
 - treatment with warfarin or aspirin vs. placebo, 450
- Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W) trial, 418
- Aurora-B/AIM-1, 7, 133
- autoantibodies, interference with platelet surface function, 85, 236
- autoerythrocyte sensitization syndrome, 148
- autoimmune lymphoproliferative syndrome, 29, 164
- autoimmune platelet dysfunction
 - and platelet function disorders, 85, 236
- automated analysis
 - platelet size and appearance, 24, 156
- Axl receptor
 - for Gas6, 53, 194
- azathioprine
 - for ITP, 28, 162
- AZD 6140, 302, 344, 398, 429
- β -thromboglobulin (β TG), 2, 126
- β_1 integrin
 - cytoplasmic domain of, 28, 162
 - gene encoding, 28, 162
- β -galactosidase
 - in lysosomes, 3, 127
- β -glucuronidase
 - in lysosomes, 3, 127
- β -lactam antibiotics, and iatrogenic platelet disorders, 82, 231
- β -thromboglobulin (β TG)
 - measurement of plasma levels, 11, 139
 - PGE₂ and, 62, 210
- β -tubulin isoform
 - absence of, 4, 128
- bacterial sepsis
 - as splenectomy risk, 27, 161
- bacterial testing, for platelet transfusions, 87, 243
- Bak alloantigen, 27, 160
- barbourin, 346
- Basel Stent Kosten-Effektivitats Trial–Late Thrombotic Events (BASKET-LATE) study, 417
- basic fibroblast growth factor (bFGF), 109, 262
- Bcl-2, 13, 136
- Bcl-3 protein, 299
- Bcl-x_L, 13, 130
- Becker, R.P., 8, 134
- Behnke, O., 8, 12, 134, 140
- beraprost, 349, 463
- Bernard–Soulier syndrome (BSS), 2, 21, 22, 28–29, 38, 85, 108, 126, 150, 163, 166, 236, 255
 - molecular defects, 55, 202
 - possibility for platelet study, 7, 132
- Bessis, M., 8, 134
- betahexosaminidase
 - in lysosomes, 3, 127
- BgII restriction fragment length polymorphism (BgII), 29, 163
- Bigalke, B., 302
- bilirubin
 - impact on platelet transfusion outcome, 95, 250
- Billroth, T., 311
- bioprosthetic valves
 - stroke risk and, 451
 - thromboembolism from, 114, 267
- biotinylated idraparinux (SSR126517), 371
- bivalirudin, 350, 372, 427
 - with GP IIb/IIIa inhibitor, 425

Index

- bleeding
 - anticoagulants vs. antiplatelet therapies, 378
 - aspirin and, 408
 - clopidogrel with aspirin and, 378
 - essential thrombocythemia (ET) and, 53, 191
 - gastrointestinal, aspirin and, 378
 - GP IIb/IIIa inhibitors dose and, 426
 - with oral anticoagulation, 465
 - PFA-100 for evaluating interoperative risk, 7, 133
 - postoperative, aspirin and, 476
 - therapeutic platelet transfusions, 99, 251–254
 - warfarin and, 377
- bleeding disorder
 - impaired epinephrine-induced aggregation and, 45, 186
 - inspection for subcutaneous, 13, 147
 - prolonged in EP3 knockout mice, 67, 214
- bleeding patient
 - differential diagnosis, 21, 150
 - focused medical history and general physical exam, 15, 149
 - initial urgent measures, 13, 147
- bleeding time, 3, 127
 - cardio-pulmonary bypass procedure and, 98, 252
 - and hematocrit, 99, 253
 - PFA-100 versus, 7, 133
 - and platelet count, 93, 245
- bleeding time (BT)
 - limitations for screening, 69, 226
 - as platelet function test, 386
- blood
 - platelet biogenesis in, 12, 140
 - shed vs. venous
 - platelet number and MMP-2 content, 68, 216
- blood coagulation cascade, 54, 194
- blood coagulation factors, 23, 152
- blood loss
 - estimating extent, 13, 147
- blood sampling, 1, 124
 - preventing artefactual in vitro platelet activation, 9, 137
- blood thrombogenicity, and glycemic control, 285
- blood transfusion
 - and bleeding, 23–24, 152
- blood vessel injury
 - platelet reponse to, 54, 201
- blood-borne metastasis, 312
- BM-567, 348
- BM-573, 348
- Boersma, E., 425
- Bolzano variant, 55, 202
- Bombeli, T., 295
- bone marrow
 - platelet biogenesis in, 12, 140
 - suppression by clopidogrel, 380
 - ticlopidine side effects on, 413
- bone marrow examination
 - for thrombocytosis evaluation, 53, 192
- Born, GVR, 4, 128
- Boston Area Anticoagulation Trial for Atrial Fibrillation, 449
- Br polymorphism
 - and fetoneonatal alloimmune thrombocytopenia (FNAIT), 29, 163
- Bresalier, R., 452
- bronchial asthma
 - chronic inflammation and airway remodelling, 330
- BT. *See* bleeding time (BT)
- buffy coat method of platelet preparation, 86, 242
- CAD. *See* coronary artery disease (CAD)
- café-au-lait spots
 - in Fanconi's anemia, 107, 255
- calcium
 - deficient homeostasis, 285
 - in dense granules, 2, 126
 - rise in intracellular, 14, 148
- calcium-calmodulin, 15, 149
- calmodulin, 24, 152
- cAMP
 - agents acting on, 348
- cAMP synthesis
 - epinephrine to inhibit, 45, 186
 - suppression of, 41, 169
- cancer
 - role of screening, 316
 - thrombin impact on dormancy, 317
 - and thrombosis, 227
 - historical perspective, 311
 - laboratory findings in hypercoagulation, 311
 - platelet role in metastasis, 312
 - thrombin role, 313
 - tissue factor role, 313
 - tumor cell adhesion, 312
- cancer cells
 - release of MMP-2 and platelet aggregation, 56, 202
- cangrelor, 302, 344, 398, 429
- capillary bleeding
 - petechiae from, 14, 147
- CAPRIE trial, 396
- carboxylate-polystyrene particles, 63, 212
- cardiac valves
 - replacement and stroke risk, 451
 - thromboembolism from, 450
- cardiopulmonary bypass procedures
 - and platelet activation, 98, 252
- cardiovascular death
 - risk in PAD patients, 458
- cardiovascular disease, 99, 251–254
 - antiplatelet therapies to prevent, 460
 - and cigarette smoking, 109, 264
 - endothelial dysfunction and, 98, 252
 - low-dose aspirin for, 462
- cardiovascular morbidity and mortality
 - particulate impact on, 63, 212
- carotid artery stenosis, aspirin for, 438
- carotid endarterectomy, 437
 - aspirin for stroke prevention after, 441
- carotid stenting, abciximab for, 447
- caspases, 13, 147

- catalase, 3, 126
- catecholamines
in dense granules, 2, 126
- cathepsin
in lysosomes, 3, 127
- cathepsin G, 299
leukocyte-derived, 114, 267
- CBFA2 transcription factor
and familial thrombocytopenia-leukemia, 39, 167
- CCI (corrected count increments), 93, 246
- CD36 receptor, 21, 29, 150, 163
polymorphisms, 30, 164
- CD40 ligand (CD40L), 82, 112, 231, 266, 324
elevated serum levels and risk for coronary event, 298
and leukocyte functioning, 114, 267
release from activated platelets, 298
- CD62P. *See* P-selectin (CD62P)
- CD84, 47, 189
- celecoxib, 452
- cellular cross talk with endothelial cells, leukocytes, platelets,
106, 255
platelet-endothelial interaction, 106, 255
cell adhesion, 110–111, 266
signaling, thrombosis, and inflammation, 111, 266
platelet-leukocyte cross talk, 61, 268
adhesion, 112, 267
signaling, thrombosis, and inflammation, 113, 267
- cephalosporins, bleeding and abnormal platelet function
from, 82, 231
- cerebrovascular diseases. *See also* stroke
aspirin for, 280
atherosclerosis and, 279
ischemic, 288
limitation of mechanical interventions, 437
uniqueness of, 437
- CHADS-2 clinical rule, 61, 268
- chamber-based thrombosis
clinical presentation, 114, 267
risk factors for, 114, 267
treatment and prevention, 115, 269
- CHARISMA (Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management, and Avoidance)
study, 80, 229, 396, 443
- Chediak-Higashi syndrome (CHS), 61, 209
- chemokine receptors, 325
- chemokines, 53, 192, 227
as immune function regulators, 107, 255
as primer, 59–60, 208
- Chimeric 7E3 Antiplatelet Therapy in Unstable angina Refractory
to standard treatment (CAPTURE) trial, 422
- Chimowitz, M., 449
- Chinese Acute Stroke Trial (CAST), 439
- cholesterol ester transfer protein (CETP) inhibitor, 109, 264
- chronic contact dermatitis, 333
- chronic critical limb ischaemia, 458
- chronic myelogenous leukemia (CML)
abnormal platelet function in, 85, 234
- chronic obstructive pulmonary disease (COPD), 332
- chronic thrombocytopenia
prophylactic platelet transfusions for, 96, 250
- cilostazol, 116, 270, 349, 463
and abnormal platelet function testing, 82, 231
for arterial thrombosis treatment and prevention,
110–111, 266
as platelet inhibitor, 87, 243
- circulating agonists
and platelet activation, 282
- cirrhosis, 83, 232
- claudication and antiplatelet drugs, 462
- clinical resistance, 352
- Clinical Trial of Rivaroxan and Metabolic Modulation in Acute
Myocardial Infarction Treatment Evaluation (CREATE),
370
- clonal thrombocytosis (CT), 45, 186
vs. reactive, 53, 191
- clopidogrel, 79, 86, 115, 228, 236, 269, 343, 413, 473
for ACS patients, 374
for acute coronary syndrome patients, 414
vs. aspirin, for PAD, 461
with aspirin, 378, 442
in atrial fibrillation, 418
for cerebrovascular disease, 323
guidelines for cessation prior to surgery, 86, 236
inadequate response to, 353
interaction with atorvastatin, 417
interindividual variability in response to, 417
ischemic event prevention, 414
laboratory monitoring of efficacy and resistance, 80,
229
measuring platelet responses to, 390
metabolism of, 344
in patients with ST-elevation MI (STEMI), 417
pharmacodynamics, 413
pharmacokinetics, 413
platelet inhibition, 396
as platelet inhibitor, 87, 243
and priming activity, 70, 227
resistance, 397, 417
risks of, 379
side effects, 380
vs. ticlopidine, for stent placement, 419
variation in response to, 392
- Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic
carotid Stenosis (CARESS) trial, 444
- Clopidogrel and Aspirin in the Management of Peripheral
Endovascular Revascularization (CAMPER) study, 466
- Clopidogrel and Metoprolol in MI (COMMIT) trial, 418
- Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–TIMI
28 trial, 417
- Clopidogrel Aspirin Stent International Cooperative Study
(CLASSICS), 415
- Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance
(CHARISMA) trial, 414
- Clopidogrel for the Reduction of Events During Observation
(CREDO) trial, 416, 444

Index

- Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, 410, 442
 clopidogrel resistance, 5, 129
 Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study, 110, 266, 414, 442
 CLOSURE trial, 453
 clot formation, collecting data on, 391
 clot signature analyzer, 69, 227
 clot time, 69, 227
 clotting factors
 degradation of, 23, 152
 neutralization by autoantibodies, 24, 152
 coagulation
 future research, 87, 244
 influence on platelets, 79, 238
 overview, 82, 232
 platelet procoagulant activity, 82–87, 244
 α -granule proteins, 85, 235
 defects, 85, 236
 effect of antagonists on, 87, 243
 heterogeneity of platelets, 86, 236
 microvesicles, 84, 234
 phosphatidylserine (PS) exposure, 83, 233
 tissue factor, 86, 243
 platelets' effect on, 22, 232
 platelet products enhancing TF synthesis, 79, 228
 vascular endothelium and, 92, 244
 coagulation cascade
 activation, 283
 pathway, 374
 coagulation factors
 acquired deficiency, 23, 151
 as platelet-derived mediators, 108, 261
 coagulation-type bleeding disorder, 21, 150
 COAT platelets, 86, 237
 coated platelets, 86, 236
 cofilin, 43, 173
 collagen, 86, 236, 308
 $\alpha_2\beta_1$ integrin as cell surface receptor for, 28, 161
 binding sites, 30, 164
 PECAM-1 braking effect on signaling, 47, 187
 and platelet activation in vivo, 39, 167
 platelet adhesion to, 21, 150
 and platelet aggregation, 5, 131
 platelet receptors for, 341
 platelet response to, 29, 162
 response to, 60, 207
 Collagen/ADP (CADP) CT, 395
 Collagen/Epinephrine (CEPI) CT, 395
 Combination Hemotherapy and Mortality Prevention (CHAMP) trial, 375
 combined antiplatelet/anticoagulant treatment role, 374
 Comparison of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide (COMPARE) trial, 422
 Cone and Plate(let) Analyzer, 8, 134
 congenital disorders
 and bleeding, 13–15, 150
 congenital platelet disorders
 α -granule defects, 61
 α -storage pool deficiency, 59, 61, 207, 209
 Jacobsen syndrome (JS), 63, 211
 Medich platelet disorder, 63, 211
 Paris Trousseau syndrome (PTS), 63, 211
 Quebec platelet disorder (QPD), 62, 210
 White platelet syndrome (WPS), 63, 211
 α,δ -storage pool deficiency, 63, 211
 Chediak–Higashi syndrome (CHS), 209
 hereditary thrombocytopenia, 209
 Hermansky–Pudlak syndrome (HPS), 208
 adhesive protein hereditary defects, 67, 215
 basics, 54, 201
 classification, 54, 201
 future research, 69, 216
 membrane phospholipids abnormalities
 Scott syndrome, 66, 213
 Stromorken syndrome, 66, 214
 Montreal platelet syndrome, 67, 215
 platelet receptor abnormalities for adhesive proteins, 55, 201
 Bernard–Soulier syndrome (BSS), 201
 Glanzmann's thrombasthenia (GT), 203
 GPIa/IIa (α_2/β_1) abnormalities, 56, 204
 GPVI abnormalities, 57, 204
 von Willebrand disease (VWD), 56, 202
 platelet receptor abnormalities for soluble agonists, 57, 204
 α_2 -adrenergic receptors, 58, 206
 P2Y₁ receptor abnormalities, 57, 204
 thromboxane A₂ receptor defects, 58, 205
 prevalence and diagnostic evaluation, 68, 215
 primary secretion defects, 67, 214
 signal-transduction pathways abnormalities, 64, 212
 arachidonic acid (AA) impaired liberation from membrane phospholipids, 63, 212
 cyclooxygenase defects, 64, 212
 GTP-binding proteins abnormalities, 65, 212
 phospholipase C activation defects, 65, 213
 thromboxane synthetase, 64, 212
 treatment of inherited disorders, 68, 216
 congenital thrombocytopenias in infants, 100, 254
 congenital thrombocytosis, 186
 congestive heart failure (CHF), 114, 267
 contact dermatitis, 333
 Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complication (CADILLAC), 428
 COPD (chronic obstructive pulmonary disease), 332
 cordocentesis, 173
 coronary artery bypass surgery (CABG)
 platelet transfusion impact, 99, 253
 coronary artery disease (CAD)
 atherosclerosis and, 279
 coagulation cascade activation, 283
 diabetes as risk factor, 285
 endothelial dysfunction, 279
 oral anticoagulants in treatment, 374
 platelet activation and aggregation process, 280–283
 platelet derived microparticles, 284
 platelet glycoprotein polymorphisms, 284

- coronary heart disease, Framingham Heart Study Prediction Score for, 109, 262
- coronary thrombosis
 - larger platelets and, 3, 127
- corrected count increments (CCI), 93, 246
- corticosteroids
 - for chronic ITP, 28, 161
- Coumadin, 316
- Coumadin Aspirin Reinfarction Study (CARS) trial, 375
- COX isoforms
 - inhibition, 115, 269
- COX-1, 342
 - aspirin inhibition of, 393
- COX-2, 342
- COX-2 inhibitors and NSAIDs
 - effect on stroke risk, 452
- COX-2 selective inhibitors, 115, 269
- COX-2 specific inhibitors, 81, 230
- C-reactive protein, 112, 266
- C-reactive protein level (CRP), 53, 192
 - and PAD, 287
 - and risk of stroke, 288
- CREST study (Clopidogrel Resistance and Stent Thrombosis Study), 398
- critical limb ischaemia
 - chronic, 458
 - prostaglandins for, 463
- Crohn's disease, 333
- CT. *See* clonal thrombocytosis (CT)
- C-terminal side
 - of α IIb and β 3 chains, 25, 157
- CTX family, 47, 189
- CURE trial, 396, 414
- CXC chemokines
 - and coronary artery disease, 69, 226
- cyclins, 7, 133
- cyclooxygenase
 - aspirin inhibition of, 342, 343
 - defects, 64, 212
- cyclopentyltriazolopyrimidines, 429
- cyclophosphamide
 - for refractory ITP, 28, 162
- cyclosporine
 - impact on platelet transfusion outcome, 95, 250
 - for refractory ITP, 29, 162
- "cysteine switch" motif (PRCGXPD), 55, 202
- cystic fibrosis, 332
- Cyt P450 enzymes
 - and clopidogrel conversion, 353
- cytochalasin, 11, 139
- Cytochrome P450
 - individual variability of activity, 397
- cytokines, 53, 192
 - as primer, 25, 208
 - chemokines, 59–60, 208
 - human studies, 69, 226
 - leptin, 60, 208
 - thrombopoietin (TPO), 58, 206
- vascular endothelial growth factor (VEGF), 58, 205
- cytokines and cytokine-like factors
 - as platelet-derived mediators, 108, 255
- cytoplasm, 7, 133
- cytoplasmic mediators, 327
- cytoskeleton
 - of resting platelet, 3, 127
- cytosolic free calcium, 282
- cytosolic free concentration
 - in activated platelets, 42, 171
- dabigatran etexilate, 373
- Dale, G.L., 86, 242
- danaparoid, 475
- danazol
 - for ITP, 27, 161
 - for refractory ITP, 28, 162
- DAVID study, 461
- Day, S.M., 81, 229
- dazoxiben, 347
- DDAVP (L-deamino-8-o-arginine vasopressin), 83, 233
- D-dimer assay, 107, 270
- DeBruyn, P.P., 8, 134
- deep vein thrombosis (DVT), 116, 270, 367, 471
- Defrey, G., 64, 212
- demarcation membrane system (DMS), 7, 133
- dendritic cells
 - platelet interaction with, 328
- dense granules, 1, 2, 93, 125, 126, 246
 - absence of, 85, 236
 - contents release by, 15, 149
 - sCD40L and, 56, 204
- dense tubular system (DTS), 3, 127
- depression
 - ITP and, 26, 157
 - serotonin and, 351
- desmopressin
 - for inherited platelet disorders, 68, 216
- dexamethasone
 - for ITP, 26, 27, 158, 160
- dextran, anticoagulant activity of, 85, 235
- diabetes mellitus, 100, 254
 - and cardiovascular risk, 109, 264
 - as risk factor for CAD, 285
- diacylglycerol, 41, 171
- dialysis, 83, 232
- diclofenac, and vascular events, 452
- diesel exhaust particles
 - impact on platelet activation, 68, 215
- DiGeorge syndrome, 37, 166
- DiGeorge/velocardiofacial syndrome, 55, 202
- dilutional thrombocytopenia and trauma, 98, 252
- dipyridamole, 346, 473
 - for arterial thrombosis treatment and prevention, 110, 266
 - for cerebrovascular disease, 445
 - effect on thromboprophylaxis, 309
 - relationship with cilostazol, 349

Index

- dipyrimadole
with aspirin, 396
- direct thrombin inhibitors (DTI)
antithrombotic therapy with, 372
- disintegrins, 345
- disseminated intravascular coagulation, 23, 83, 152, 233
trauma and, 97, 251
- Do Tirofiban and ReoPro Give Similar Efficacy Trial (TARGET), 422
- Dohle-like bodies, 37, 166
- drug-induced thrombocytopenia, 41, 167
from heparin, 41, 168
- drug interaction
and pharmacodynamic resistance, 352, 353
- drugs
affecting platelet function, 13, 130
- DTI. *See* direct thrombin inhibitors (DTI)
- Duke bleeding time, 3, 127
- Dutch Bypass Oral anticoagulants or aspirin study, 464
- DVT risk in hospitalized medical patients, 271
- dynactin, 10, 139
- dynein, 4, 10, 11, 128, 139
- dysfibrinogenemia, 68, 215
- dysmegakaryocytopoiesis, 106, 255
- ecchymosis, 14, 148
- Echis carinatus*, 346
- echistatin, 346
- Eckert, B., 447
- EDRF, 13, 147. *See* endothelium-derived relaxing factor (EDRF)
nitric oxide (NO)
- EDTA
and low platelet count, 1, 124
- Efficacy and Safety of Subcutaneous Enoxaparin versus
intravenous unfractionated heparin, in Non-Q-wave
Coronary Events (ESSENCE) trial, 370
- EGF. *See* epidermal growth factor (EGF)
- Ehlers–Danlos syndrome, 21, 150
- eicosanoids
as platelet-derived mediators, 109, 263
- elastin
gelatinase A ability to hydrolyze, 56, 202
- electrospray, 13, 141
- ELISA
plasma sample storage, 13, 140
- Eltrombopag
for refractory ITP, 29, 163
- emergency treatment
for ITP, 26, 159
- ENA-78, 60, 207
- end-binding protein three (EB3), 10, 138
- endogenous protein synthesis
and α granules, 1, 125
- endomitosis, 5, 6, 131, 132
- endoperoxide analog U46619
succinate and, 64, 212
- endothelial cells
cellular cross talk with platelets and leukocytes, 106, 255
- dysfunctional state in vascular inflammation, 109, 265
- functions, 109, 264
- platelet adhesion to, 294
- platelets and, 315
- secretion of chemokines, 294
- endothelial differentiation gene (Edg)-1, 315
- endothelial NOS (eNOS), 96, 109, 250, 265
- endothelium
circulating cells adhesion to activated, 324
- prothrombotic shear-dependent factors release by, 108, 261
- See also* vascular endothelium
- endothelium-derived relaxing factor (EDRF), 92, 95,
244, 250
- endotoxin
in vitro effects on platelets, 63, 211
- Enhanced Suppression of the Platelet IIb/IIIa Receptor with
Integrilin Therapy (ESPRIT) trial, 422
- enoxaparin, 370
- Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial
Infarction Treatment-Thrombolysis In Myocardial
Infarction study 25 (EXTRACT-TIMI 25), 370
- enteric coating of aspirin, 342
- enteric-coated aspirin
pharmacokinetic resistance with, 352
- eph receptor tyrosine kinases, 47, 190
- ephrins, 47, 189
- epidermal growth factor (EGF), 109, 262, 315
platelet release of, 330
- epinephrine, 45, 186
defective platelet response to, 58, 206
- mice studies
in vivo effect, 66, 213
- myeloproliferative disorders and, 84, 234
- and platelet aggregation, 5, 131
- as primer, 61, 209
- succinate and, 64, 212
- and variable bleeding tendency, 69, 227
- epistaxis, 14, 147
- epithelial neutrophil activating protein-78 (ENA-78; CXCL5),
108, 255
- epoprostenol
and abnormal platelet function testing, 82, 231
- Epstein Syndrome, 108, 255
- Epstein, E., 47, 187
- eptifibatide, 81, 229, 346, 392, 419
for arterial thrombosis treatment and prevention, 112, 266
- bleeding complications, 379
- pharmacokinetics, 419
- recommended for PCI treatment, 422
- thrombocytopenia from, 380
- erythrocytes
in arterial thrombosis, 108, 261
- erythroid-megakaryocytic progenitor, 5, 132
- erythromelalgia, 47, 189
- erythropoietin
anemia from deficiency, 82, 232
- E-selectin (CD62E), 110, 266, 296, 324
- ESPRIT study, 445

- estrogens
as primer, 61, 209
- ET. *See* essential thrombocythemia (ET)
- eukaryotic cells
phospholipids in, 83, 232
- European Atrial Fibrillation Trial (EAFT), 376, 450
- European Stroke Prevention Study-1 (ESPS-1), 445
- European Stroke Prevention Study-2 (ESPS-2), 445
- Evaluation in PTCA to Improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade (EPILOG), 419
- Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial, 419
- Evaluation of Platelet Inhibition in STENTing (EPISTENT) trial, 419
- Evans syndrome, 39, 166
- exercise
MPV (mean platelet volume) and, 3, 126
- exosomes
vs. microvesicles, 84, 234
- extended stored platelets
for transfusions, 92, 244
- Extension stage for hemostatic plug, 25, 37, 166, 187
- adenosine 5'-diphosphate (ADP), 43, 175
- epinephrine, 45, 186
- G protein-mediated signaling, 41, 167
- G_q and activation of phospholipase C β , 41, 171
- G_q G₁₃ and actin cytoskeleton, 43, 169–172
- platelet activation in vivo, 41, 171
- signaling through G_i family members, 43, 175
- thrombin, 45, 176
- thromboxane A₂ (TxA₂), 46, 186
- extracellular matrix (ECM), platelets and composition of, 330
- extreme thrombocytosis
platelet count, 46, 186
- extrinsic tenase, 83, 232
- Fabre, J.E., 67, 214
- Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) study, 429
- factor IIa. *See* thrombin
- factor IXa, 54, 201
- factor V, 54, 85, 201, 235
deficiency, 22, 151
Leiden mutation, 85, 235
plasma vs., platelet, 85, 235
- factor V Leiden, 310
- factor Va, 54, 201
- factor VII
deficiency, 21, 150
levels in diabetes mellitus-type II, 286
- Factor VIIa, 80, 229
- Factor VIII
as platelet primer, 54, 194
- factor VIIIa, 54, 79, 194, 228
- factor X
levels in diabetes mellitus-type II, 286
- factor Xa inhibitors
antithrombotic therapy with, 370–372
oral direct, 373
- factor Xa
unfractionated heparin (UFH) and, 367
- factor XI, 54, 194
platelet binding sites for, 23, 152
- factor XII
deficiency, 22, 150
- familial hypercholesterolemia (FH)
and premature coronary artery disease, 69, 216
- familial thrombocytopenia-leukemia, 39, 167
- FAMOUS trial, 317
- Fanconi's anemia, 29, 106, 163, 255
- fatigue
ITP and, 26, 157
- Fechtner Syndrome, 108, 255
- Ferroni, P., 287
- fetal alloimmune thrombocytopenia (AIT), 43, 169–172
- fetal blood sampling (FBS), 43, 172, 173
- fetoneonatal alloimmune thrombocytopenia (FNAIT), 99, 254
Br polymorphism and, 29, 163
Pen/Yuk and, 27, 160
- fibrin clots
and platelet procoagulant activity, 84, 234
and thrombin generation, 86, 236
- fibrin meshwork, 472
- fibrin monomer
and platelet-tumor cell adhesion, 312
- fibrinogen, 82, 97, 108, 231, 251, 261
 $\alpha_{IIb}\beta_3$ integrin as receptor, 24, 156
anti-PIA antibodies inhibiting binding, 27, 159
binding to $\alpha_{IIb}\beta_3$, 282
binding to GP IIb/IIIa, 95, 248
binding, 46, 187
deficiency, 22, 151
delivery to α granules, 2, 125
increased production of, 112, 266
inherited disorders, 68, 215
and leukocyte recruitment, 300
levels in diabetes mellitus-type II, 286
MMP-2 and, 56, 203
surface level of, 86, 242
- fibrinogen receptor, 345
- fibrinolysis
in Quebec platelet syndrome, 86, 236
vascular endothelium and, 92, 244
- fibrinolytic inhibitors
for inherited platelet disorders, 68, 216
- fibrinolytic
abciximab with, 428
- fibrinopeptide A (FPA)
in diabetic patients, 286
- fibrin-specific thrombolytic agents, 24, 152
- fibroblast growth factor (FGF)
platelet release of, 313

Index

- fibronectin, 345
 α granules release of, 93, 247
 surface level of, 86, 242
 Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) trial, 371
 filamin, 4, 15, 129, 149
 filamin- GPIIb α connection, 4, 129
 filamin-1, 24, 152
 filopodia, 14, 15, 148, 149, 324
 Fitzgerald, D.J., 302
 flippase, 83, 233
 floppase, 83, 233
 flow cytometric analysis of platelets, 391
 flow cytometry, 8, 134
 advantages/limitations, 9, 138
 for determining $\alpha_{IIb}\beta_3$ receptor occupancy, 392
 monoclonal antibodies, 8, 135
 platelet markers for detection, 13, 136
 fluorescein isothiocyanate (FITC), 8, 134
 fluoxetine
 and abnormal platelet function testing, 82, 231
 foam cells, 300
 fondaparinux, 370
 foods and platelet function in vitro, 82, 231
 foreign substances
 as primer, 63, 212
 Forer, A., 12, 140
 Fragmin during Instability in Coronary Artery Disease (FRISC) trial, 368
 Fragmin in unstable coronary artery disease study (FRIC) trial, 368
 Framingham Heart Study Prediction Score, for coronary heart disease, 109, 262
 Framingham study, 287
 free fatty acids
 insulin and release of, 285
 FXI
 activation by thrombin, 83, 232

 λ granules, 327
 G₁₃
 and actin cytoskeleton, 43, 169–172
 Gabbeta, J., 64, 212
 Galt, S.W., 55, 202
 gamma irradiation, for platelet transfusions, 92, 244
 gangrene
 purpura fulminans and, 15, 149
 Gas-6. *See* growth-arrest specific gene 6 (Gas-6)
 Gasic, G., 312
 gastric acid production, aspirin and, 110, 265
 gastric ulcer, healing, 316
 gastrointestinal system
 bleeding, aspirin and, 79, 228, 378
 side effects from clopidogrel, 380
 GATA1
 syndromes of abnormalities, 39, 167
 gelatinase A (MMP-2)
 as platelet primer, 55, 202
 and VEGF release, 58, 206

 gelsolin, 14, 148
 gene expression, 13, 141
 gene therapy, 355
 Gent, M., 444, 475
 ghrelin, 61, 208
 G_i family, 41, 169
 signaling through members, 43, 173
 Giesen, P.L., 79, 228
 Girolami, B., 463
 Glanzmann's thrombasthenia (GT), 24, 56, 126, 156, 203
 global platelet function
 bleeding time, 3, 127
 rapid platelet function assay, 4, 128
 Global Use of Strategies to Open Coronary Arteries (GUSTO) study group, 378
 Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb trial, 372
 Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries (GUSTO) IV-ACS trial, 423
 glucocorticoids
 for ITP, 26, 158
 glycated LDL, in hyperglycaemia, 286
 glycemic control
 and blood thrombogenicity, 285
 glycoprotein (GP) Ib/IX/V complex, 21–24, 150, 156, 324
 and adhesion, 94, 248
 platelet deficiency, 54, 201
 polymorphisms of, 24, 156
 signaling and functions, 23–24, 155
 structure, 22–23, 152
 glycoprotein (GP) Ib α , 282
 glycoprotein (GP) IIb/IIIa complex
 and thrombus growth, 95, 248
 glycoprotein (GP) polymorphisms, 284
 glycoprotein Ib
 MMP-2 and, 56, 203
 glycoprotein IIb/IIIa antagonists, 261
 as block for fibrinogen binding, 261
 effort to develop orally active, 346
 glycoprotein IIb/IIIa inhibitors, 418–429
 See also abciximab; eptifibatide; tirofiban
 for arterial thrombosis treatment and prevention, 112, 266
 benefit in patients undergoing PCI, 422
 clinical studies, 419
 dosing and relationship with bleeding, 426
 in NSTEMI ACS, 422–426
 patient subgroups with enhanced benefits, 423
 upstream vs. periprocedural administration, 425
 vs. other antithrombotic agents, 426–429
 overdosing, 426
 in patients with STEMI, 428–429
 pharmacodynamics, 419
 pharmacokinetics, 419
 and secondary stroke prevention, 447
 for stroke treatment and secondary prevention, 329
 glycoprotein V (GPV), 11, 139
 glycyl-L-prolyl-L-arginyl-L-prolin (GPRP), 10, 138
 Goedel, A., 47, 187

- GOLD (AU-assessing Ultegra), 393
- Gorelick, P., 444
- GP Ia/IIa (α_2/β_1)
abnormalities, 56, 204
- GP Ib α , 82, 84, 231, 234
- GP IIb/IIIa, 108, 261
- GP IIb/IIIa (α_{IIb}/β_3)
abnormalities, 56, 203
- GPCRs, 40, 167
- GPIa (α_2 integrin), 29, 163
- GPIa/IIa (α_2/β_1) abnormalities, 56, 204
- GPIb α , 22, 151
binding, and atherogenesis, 296
- GPIb α gene
defects, 55, 202
- GPIb β , 22, 151
amino acids, 22, 151
- GPIb/IX/V complex
time dependence of platelet surface expression,
9, 138
- GPIb β gene
defects, 55, 202
- GPIIb (α_{IIb} integrin), 27, 161
- GPIIb/IIIa receptor antagonists, 116, 269
- GPIIb-IIIa complex
MoAbs and, 9, 136
- GPIIIa (β_3 integrin), 27, 159
- GPIIIb, 29, 163
- GPIV, 29, 163, 324
- GPIX, 22, 151
amino acids, 23, 151
- GPIX gene
defects, 55, 202
- GPVI, 21, 22, 23, 30, 39, 150, 151, 164, 167
abnormalities, 56, 204
adhesion initiation by, 110, 265
collagen and clustering of, 39, 167
platelet surface expression, 302
polymorphisms, 30, 164
- G_q
and actin cytoskeleton, 43, 169–172
and activation of phospholipase C β , 41, 171
- Gq-linked receptor P2Y₁, 343
- graft material
for peripheral bypass, 464
- graft-versus-host disease (GVHD)
impact on platelet transfusion outcome, 95, 250
preventing, 92, 244
- gram-negative bacteria
lipopolysaccharides (LPS) release from, 63, 211
- granules, 1, 124
contents release by, 15, 149
mechanism of movement, 11, 139
mediators released, 325
secretion, 15, 149
- granulophysin, 60, 207
- gray platelet syndrome, 3, 61, 108, 126, 209, 255
- green fluorescent protein (GFP) technology, 9, 138
- Gross, P.L., 80, 229
- growth factors
as platelet-derived mediators, 108, 261
- growth-arrest specific gene 6 (Gas-6), 47, 190
human studies, 68, 215
mice studies
in vivo effect, 64, 212
as platelet primer, 53, 193
- growth-regulating oncogene- α (Gro- α ; CXCL1), 108, 255
- Gro- α gene, 313
- GTP-binding proteins
low molecular weight in Rho family, 43, 173
- GTP-binding proteins abnormalities, 65, 212
- guanidinosuccinic acid (GSA)
accumulation of, 83, 232
- guanine nucleotide exchange factor (GEF), 43, 173
- guanosine 5'-diphosphate (GDP), 41, 165–167
- guanosine 5'-triphosphate (GTP), 41, 165–167
- guanylyl cyclase, 82, 231
- Gurbel, P.A., 398
- GUSTO-V trial, 428
- H. pylori*
testing for, 25, 156
and thrombocytopenia, 25–26, 157
- hematoma, 15, 149
- hemophilia, 22, 150
acquired A, 24, 152
and subcutaneous hematomas, 15, 149
- hemorrhage. *See* bleeding; intracranial haemorrhage (ICH)
- Hemoscope TEG, 391
- Haemostasis Analysis System (HAS), 391
- hairy cell leukemia, 84, 234
- Haller, C.J., 8, 135
- Hansson, L., 438
- Hass, W., 444
- Hayden, M., 408
- HDL-cholesterol
as atherosclerotic biological marker, 293
- Heart failure Long-term Antithrombotic Study (HELAS) study,
376
- heat shock proteins
and oxidative stress, 99, 254
- hematocrit
and bleeding time, 99, 253
- hemodialysis, 83, 232
- hemolysis
intravascular (IVH), 27, 160
- hemolytic uremic syndrome (HUS), 37, 43, 165, 175
- hemophilias, 79, 83, 228, 232
- hemorrhages, intracranial (ICH)
in AIT, 41, 171
in utero, 41, 171
- hemorrhagic stroke, 437
- hemostasis
abnormalities in cancer, 311
blood-borne TF role in, 81, 229

Index

- hemostasis (*Contd.*)
 low-dose and frequent transfusions, 97, 251
 platelet-endothelial interaction in, 94, 248
- hemostatic plugs, 79, 227
See also coagulation
- hemostatic system
 platelets in, 93, 245
- hematopoietic stem cells
 megakaryocytes derived from, 5, 131
- Henoch Schönlein purpura, 15, 149
- heparanase, 327
- heparin, 350, 1, 124
 with GP IIb/IIIa inhibitor, 425
 inhibition of metastasis, 312
 to reduce DVT incidence, 272
- heparin-induced thrombocytopenia (HIT), 41, 168
- heparinoids
 for arterial thrombosis treatment and prevention, 112, 267
 and DVT risk, 271
- hepatitis C
 serological evaluation for, 24, 156
 and thrombocytopenia, 25, 157
- hepatocyte growth factor (HGF), 315
- hepatocytes, 22–23, 151
- herbal medications
 and platelet function in vitro, 82, 231
- hereditary thrombocytopenia, 61, 209
- Hermansky–Pudlak syndrome (HPS), 60, 208
- heterogeneity of platelets, 86, 236
- HGF (hepatocyte growth factor), 315
- high molecular weight kininogen, 22, 151
- high-density lipoprotein cholesterol (HDL)
 and thrombus formation, 109, 264
- Hippocrates, 342
- hirudin, 1, 124, 372
- hirulog, 372
- histamine
 δ granule storage of, 326
 as primer, 61, 209
- HIV. *See* Human Immunodeficiency Virus (HIV)
- Ho, D., 447
- HOCl-LDL. *See* hypochlorous acid (HOCl-LDL)
- Hoffman, R., 447
- homocysteinemia, as atherosclerotic biological marker, 293
- hormone replacement therapy (HRT)
 and coronary events in postmenopausal women, 69, 227
- hormones, 53, 192
 human studies, 69, 227
 mice studies
 in vivo effect, 66, 213
 as primer, 61–62, 209
 epinephrine, 61, 209
 estrogens, 61, 209
 histamine, 61, 209
- HPA-2 polymorphism, 24, 155
- Huang, E.M., 64, 212
- human fibroblast collagenase (MMP-1)
 as platelet primer, 55, 202
- human immunodeficiency virus (HIV)
 and ITP, 29, 163
 serological evaluation for, 24, 156
 and thrombocytopenia, 25, 157
- Human Leukocyte Antigens (HLA), Class I
 antibodies to, 93, 247
- human platelet antigen HPA 1 a
 and FNAIT, 99, 254
- human umbilical vein endothelial cells (HUVECs)
 platelet adhesion to, 295
- hydroxychloroquine, 473
- hydroxyecosatetraenoic acid (12-HETE), 327
- hydroxyurea
 and leukemia, 54, 194
- hydroxyurea, 353
 from acquired von Willebrand syndrome, 84, 234
- hypercholesterolemia, 100, 254
 familial (FH) and premature coronary artery disease,
 69, 216
- hypercoagulability in cancer, 311
 laboratory findings, 311
- hyperfibrinogenemia, in cancer patients, 311
- hyperglycaemia
 glycated LDL in, 286
 and nuclear factor kappa B (NF- κ B), 285
- hyperhomocysteinemia, 109, 265
- hyperpigmentation, in Fanconi's anemia, 107, 255
- hypertension, 99, 109, 254, 262
- Hypertension Optimal Treatment (HOT) trial, 408
- hypobaric hypoxia
 and haemostasis, 478
- hypochlorite-modified proteins
 in atherosclerotic plaques, 57, 204
- hypochlorous acid (HOCl-LDL)
 LDL oxidized by, 57, 204
- hypodysfibrinogenemia, 68, 215
- hypofibrinogenemia, 68, 215
- hyposplenism, 46, 187
- hypotension
 and need for fluid replacement, 13, 147
- hypothermia in trauma patients
 and platelet dysfunction, 98, 252
- Hzf (hematopoietic zinc finger protein)
 zinc and, 63, 211
- ibuprofen
 and vascular events, 452
- ICAM-2, 324
- ICH. *See* intracranial haemorrhage (ICH)
- Ichor full blood counter, 390
- idraparinux sodium, 371
- IgE in platelet chemotaxis in allergic inflammation, 328
- IL-8 (interleukin-8), 60, 207
- iloprost, 349
- immune defence mechanisms, platelet role in, 334
- immune function
 chemokines as regulators, 107, 255
 platelets role in, 341

- immune thrombocytopenic purpura (ITP), 37, 155–165
 - additional clinical features, 26, 157
 - in childhood, 37, 163–165
 - differential diagnosis, 29, 163
 - management at presentation, 30, 164
 - managing acute after first week, 30, 164
 - managing chronic after 6–12 months, 30, 165
 - chronic, 28, 161
 - chronic refractory, 28, 162
 - immunosuppression, 28, 162
 - investigational approaches, 29, 162
 - clinical management
 - emergent treatment, 9, 159–161
 - initial treatment, 26, 158
 - differential diagnosis, 24, 156
 - epidemiology and presentation, 24, 155
 - initial evaluation, 21–24, 156
 - pathogenesis and laboratory diagnosis, 25–26, 157
- immunoglobulin-type receptors, 324
- immunology
 - $\alpha_2\beta_1$ integrin, 28–29, 163
 - polymorphisms, 29, 163
 - signaling, 29, 162
 - structure, 28, 162
 - $\alpha_{IIb}\beta_3$ integrin, 9, 159–161
 - affinity regulation, 26, 157
 - clinical relevance and future directions, 27, 161
 - epitopes location for conformation-dependent mAbs, 26, 159
 - ligand-binding site location, 26, 158
 - polymorphisms, 11, 161
 - structure, 25–26, 157
- CD36 receptor, 29, 163
 - polymorphisms, 30, 164
- future research, 31, 165
- glycoprotein (GP) Ib/IX/V complex
 - polymorphisms of, 24, 156
 - signaling and functions, 23–24, 152
 - structure, 22–23, 151
- GPVI, 30, 164
 - polymorphisms, 30, 164
- impact cone and plate(let) analyzer, 69, 227, 390
- impedance (whole blood) platelet aggregometry, 6, 132
- impedance whole blood aggregometry (WBA), 388
- Imperiale, T.E., 475
- inducible NOS (iNOS), 96, 250
- infants
 - congenital thrombocytopenias, 100, 254
 - Fanconi's anemia, 106, 255
 - response to transfusions, 93, 245
 - Thrombocytopenia with Absent Radii (TAR syndrome), 106, 255
 - Wiskott–Aldrich syndrome in, 107, 255
 - X-linked congenital thrombocytopenias, 107, 255
- infection
 - and reactive thrombocytosis, 46, 186
- inflammation
 - anti-inflammatory effects of platelet inhibition, 9, 270
 - chronic disorders
 - future research, 334
 - dermatologic diseases, 333
 - inflammatory bowel disease (IBD), 333
 - molecules produced by activated platelets, 107, 270
 - platelet chemotaxis in allergic, 328
 - platelet-derived mediators, 22, 264
 - adhesion proteins, 108, 255
 - chemokines, 107, 255
 - coagulation factors, 108, 261
 - cytokines and cytokine-like factors, 108, 255
 - eicosanoids and lipid mediators, 109, 262
 - growth factors, 108, 261
 - proteases, 109, 264
 - platelet-endothelial interaction in, 95, 250
 - role of platelets, 106, 255
 - processes, 323
 - rheumatoid arthritis, 334
- inflammatory cells
 - platelets as, 323–329
 - mediators released, 325
 - receptors involved, 324
 - structural characteristics, 323
- inherited thrombocytopenias
 - children with, 29, 163
 - myelodysplasia, 40, 167
- inherited thrombocytopenias, 41, 165–167
- initiation stage of platelet activation, 37, 39, 165, 166
- insulin
 - and platelet reactivity, 285
 - and release of free fatty acids, 285
- insulin-like growth factor (IGF), 315
 - platelet release of, 330
- integrin, 111, 266, 345
 - and platelet adhesion, 297
 - and platelet-EC adhesion, 110, 265
 - signaling, 46, 187
- integrin receptors, 21, 150
- integrin $\alpha_{IIb}\beta_3$, 392
 - and platelet adhesion, 297
- integrin $\alpha_{IIb}\beta_3$ antagonists, 81, 229
 - and bleeding, 81, 230
 - laboratory monitoring, 81, 230
- integrin $\alpha_v\beta_3$, and platelet adhesion, 297
- interferon alpha, 54, 194
- interferon- γ
 - CD40L and, 114, 267
- interleukin (IL)-1, 327
 - and reactive thrombocytosis, 46, 187
- interleukin (IL)-1 β
 - release from activated platelets, 298
- interleukin (IL)-4
 - and reactive thrombocytosis, 46, 187
- interleukin (IL)-6
 - and reactive thrombocytosis, 46, 187
- interleukin-1 β , 112, 266
 - CD40L and, 114, 267

Index

- intracellular adhesion molecule-2 (ICAM-2), 82, 231
- Intracoronary Stenting and Antithrombotic Regimen
Rapid Early Action for Coronary Treatment (ISAR-REACT 2)
trial, 425, 427
- intracranial haemorrhage (ICH)
in AIT, 41, 171
anticoagulation therapy and, 378
prevention in ITP treatment, 30, 164
spontaneous fetal, 43
from warfarin, 449
- intravascular hemolysis (IVH), 27, 160
- intravenous immunoglobulin (IVIG)
for ITP, 27, 160
- intrinsic tenase, 83, 232
- ions, 53, 191
zinc as primer, 62, 211
- ISAR-Abciximab a Superior Way to Eliminate Elevated
Thrombotic Risk in Diabetics (SWEET) trial, 426
- isbogrel, 347
- ischemic cerebrovascular diseases, 288
- ischemic events
clopidogrel for preventing, 414
- ischemic stroke, 367
- isoprostanes, 97, 251
- ITGA2B* promoter, 357
- Ivy bleeding time, 127
- Jacobsen Syndrome (JS), 63, 108, 211, 255
- JAK2V617F molecular marker, 37–48, 190
essential vs. reactive thrombocytosis, 53, 192
and ET, 53, 194
- junctional adhesion molecule-(JAM)-1, 324
- junctional adhesion molecule-C (JAM-C or JAM-3),
82, 231
- Kawasaki disease
and reactive thrombocytosis, 46, 186
- Kearney, P., 452
- kidney disease, platelet function disorders and, 82, 232
- kinesin, 4, 11, 128, 139
- kinetic platelet aggregometer, 400
- kininogen, 82, 231
high molecular weight, 112, 151, 224, 267
and leukocyte recruitment, 300
- kit ligand (KL), 13, 142
- Kozak (-5T/C) polymorphism, 24, 156
- laboratory method for platelet assessment
blood sampling, 1, 124
flow cytometric assessment, 8, 134
future research, 13, 142
global platelet function
bleeding time, 3, 127
rapid platelet function assay, 4, 128
platelet aggregation tests
agonist-induced, 5, 129
impedance (whole blood) platelet aggregometry, 132
optical (turbidometric) platelet aggregometry, 4, 128
platelet activation under controlled shear conditions, 7, 133
platelet function under flow, 8, 134
VerifyNow, 6, 132
platelet morphology tests, 125–127
platelet count, 1, 125
platelet size and appearance, 126
quantifying platelet pathophysiology, 140
soluble platelet activation markers
glycoprotein V (GPV), 139
granular contents, 11, 139
platelet adhesion assay, 9–11, 140
sP-selectin, 11, 139
study techniques, 13, 141
urinary markers
TxA₂ metabolites, 12, 140
TxB₂, 110, 12, 140
- Lages, B., 60, 208
- lamellipodia, 14, 148, 324
- laminin
 $\alpha_2\beta_1$ integrin as cell surface receptor for, 28, 161
and tumor cell adhesion, 313
- latrunculin, 11, 139
- LDL-cholesterol, as atherosclerotic biological marker, 293
- Lee, D., 447
- leg arteries, disease in, 458
- lepirudin, 372
- leptin
mice studies and in vivo effect, 66, 213
as primer, 60, 208
- Leu57Phe mutation, 55, 202
- leucine-rich glycoproteins, 324
- leukemia
acute myelogenous
d-SPD and development, 60, 208
and platelet function disorders, 84, 234
transient megakaryocytic, 41, 169
leukemia inhibitory factor (LIF), 13, 141
leukemic transformation
risk in thrombocytopenia, 53, 193
- leukocyte integrin $\alpha_M\beta_2$
affinity state change, 82, 231
- leukocytes
as risk factor for thrombosis in ET, 53, 194
in arterial thrombosis, 108, 261
binding to activated platelets, 112, 267
cellular cross talk with platelets and endothelial cells,
106, 255
enhancement of TF production, 81, 230
and platelet adhesion, 295
platelet aggregation with, 159
platelet interaction with, 308, 328
PMP enhancement of adhesion, 284
polymorphonuclear, in ischemic stroke, 288
recruitment of, 324
- leukoreduction, 87, 94, 243, 248
- Libman-Sacks endocarditis, 115, 269
- life span of platelets
in ITP, 26, 157

- ligand-binding site
 - location of, 26, 157
- light transmission aggregometry (LTA), 387
 - limitations, 388, 395
- limb ischaemia, 108, 261
 - antiplatelet treatment impact on, 462
- Lindblad, B., 441
- Lindmarker, P., 317
- lipid mediators
 - as platelet-derived mediators, 109, 262
- lipid rafts, 82, 227–232
- lipopolysaccharides (LPS)
 - mice studies and in vivo effect, 67, 215
 - as primer, 63, 211
- lipoprotein
 - as atherosclerotic biological marker, 293
- liver disease
 - platelet function disorders from, 83, 232
- liver regeneration
 - serotonin and, 2, 126
- LMWHs. *See* low-molecular-weight heparin (LMWH)
- lotrafiban, 346, 447
- low molecular weight GTP-binding proteins
 - in Rho family, 43
- low-density lipoproteins (LDL), 57, 204
 - elevated, and CAD, 109, 262
 - as platelet primer, 57, 204
- low-molecular-weight heparin (LMWH), 350
 - for anticoagulation, 367
 - aspirin compared to, 475
 - for thromboprophylaxis, 471
 - and VTE risk reduction, 479
 - vs. warfarin, for prophylaxis of VTE, 309
- LPA. *See* lysophosphatidic acid (LPA)
- LRR sequence
 - extracellular, 22, 150
- L-selectin, 324
- LTA (light transmission aggregometry), 387
 - limitations, 388, 395
- lumiaggregometry, 60, 208
- lung cancer patients
 - unfractionated and LMWH for, 317
- lungs
 - megakaryocytes in, 12, 140
 - platelet biogenesis in, 12, 140
- lupus. *See* systemic lupus erythematosus (SLE)
- lupus anticoagulant, 24, 152
- Lyman, S., 27, 161
- lymphoblastic leukemia, acute
 - abnormal platelet function in, 84, 234
- lymphoid progenitor
 - from hematopoietic stem cells, 5, 131
- lysis
 - collecting data on, 391
- lysophosphatidic acid (LPA), 58, 204, 315
- lysosomal membrane protein CD63, 2, 126
- lysosomes, 3, 126, 327
- Ma, H., 67, 214
- macrothrombocytopenias, 108, 255
- macromolecular ligand fibrinogen
 - binding site for, 26, 158
- macrophage inflammatory peptide (MIP-1; CCL3), 108, 255
- macrophage-derived chemokine (MDC), 59, 207
- macrophages
 - monocyte differentiation into, 298
- macrothrombocytopenias, 2, 21, 28–29, 126, 150, 163
 - congenital, 4, 128
- MAIPA (monoclonal antibody immobilization of platelet glycoprotein assay), 43, 171
- malignancy. *See* cancer
- MALT trial, 317
- Marcus, A.J., 81, 230
- marginal band of microtubules, 3, 128
- Martens, L., 48, 191
- Mas, J., 451
- mast cells
 - degranulation, 328
 - and matrix degeneration by proteases from, 299
- mast cell growth factor, 13, 141
- MATCH study, 396, 443
- Matetzsky, S., 397
- matrix metalloproteinase-2 (MMP-2), platelet secretion of, 298
- matrix metalloproteinases (MMP), 109, 264, 327, 330
 - CD40L and release, 298
 - human studies
 - on cardiovascular disorders, 68, 215
 - mice studies and in vivo effect, 65, 212
 - as platelet primer, 55, 202
 - zinc and, 63, 211
- matrix-assisted laser-desorption ionization (MALDI), 13, 141
- May-Hegglin anomaly, 11, 108, 139, 255
- May-Hegglin inherited thrombocytopenia (MYH9-RD), 29, 37, 163, 166
- MCP-3 (monocyte chemoattractant protein), 60, 207
- mean fluorescent intensity, 8, 135
- mean platelet volume (MPV), 2, 126
 - and acute cardiac events, 3, 127
 - exercise and, 3, 126
 - high levels as risk for coronary atherosclerosis, 3, 126
- mediators
 - platelet release of, 325
- Medical Research Council (MRC), 473
- Medich platelet disorder, 63, 211
- megakaryoblastic leukemia
 - dysfunctional platelets in, 84, 234
- megakaryocyte growth and development factor (MGDF), 354
- megakaryocyte progenitors
 - and endomitosis, 6, 132
- megakaryocytes, 323
 - classification schemes, 6, 132
 - cytoplasm conversion, 8, 135
 - development and platelet formation, 5–13, 147
 - apoptosis and platelet biogenesis, 13, 142
 - commitment to megakaryocyte lineage, 5, 131
 - cytoplasmic maturation, 7, 133

Index

- megakaryocytes (*Contd.*)
 - cytoskeletal machine of platelet production, 9–11, 140
 - endomitosis, 6, 132
 - platelet formation, 7, 133
 - platelet formation in vivo, 11, 140
 - regulation, 13, 140
 - features of mature, 7, 133
 - fragments, 12, 140
 - future research, 15, 150
 - in lungs, 12, 140
 - in TAR syndrome, 106, 255
- membrane glycoprotein α IIb β 3, 2, 125
- membrane phospholipids abnormalities
 - Scott syndrome, 66, 213
 - Stromorken syndrome, 66, 214
- membrane skeleton
 - of resting platelet, 323
- membrane systems, 3, 127
- meningococcaemia
 - purpura fulminans and, 15, 149
- menses
 - danazol to stop temporarily, 11, 161
- Mer receptor
 - for Gas6, 53, 194
- mesenchymal cells
 - thrombin as growth factor, 313
- metal ion-dependent adhesion site (MIDAS), 25, 157
- metargidin, 299
- metastasis, platelet role in, 312
- methylprednisolone
 - for ITP, 26, 158
- MGDF (megakaryocyte growth and development factor), 354
- microarray technology, 13, 141
- microparticles
 - activated platelet release of, 108, 261
 - leukocyte-derived, 300
 - platelet-derived, and atherosclerosis, 284
- microtubules
 - direct visualization of dynamics, 9, 138
 - marginal band of, 3, 128
 - and proplatelet formation, 9, 137
 - secondary function, 11, 139
- microvascular symptoms
 - in essential thrombocythemia, 47, 189
- microvesicles
 - generation of, 84, 234
 - tissue-factor bearing, 82, 231
- MIP-1 (macrophage inflammatory protein), 60, 207
- mitochondria
 - in platelets, 3, 126
- mitosis promoting factor (MPF), 7, 132
- mitral stenosis, 116, 269
- mitral valve prolapse
 - embolism prophylaxis in, 116, 269
- Mitsui, T., 66, 213
- MLL transcription factor
 - and familial thrombocytopenia-leukemia, 39, 167
- Mohr, J., 448
- molecular typing
 - for compatible donors for platelet transfusion, 94, 248
- molecules
 - in granules, 1, 124
- monoclonal antibodies (MoAbs), 8, 135
- monoclonal antibody immobilization of platelet glycoprotein
 - assay (MAIPA), 42, 171
- monocyte chemotactic protein-3 (MCP-3; CCL7), 108, 255
- monocytes, 294
 - and atherosclerotic lesion development, 298
 - complex formation with activated platelets, 81, 230
 - in ischemic stroke, 288
 - platelet activation and regulation of transformation, 298
- monomeric G proteins, 41, 169
- Montreal platelet syndrome, 67, 215
- Montrucchio, G., 63, 211
- Moroi, M., 24, 156
- morphology tests for platelets, 3, 125–127
 - platelet count, 1, 125
 - platelet size and appearance, 2, 126
- mortality rate
 - of alloimmune thrombocytopenia (AIT), 41, 171
- mouse
 - advantages for human biology study, 64, 212
- MPL (MPLW515L/K), 48, 190
- Mpl polymorphisms
 - and variation in normal platelet counts, 45, 186
- mRNA
 - platelet translation into protein, 299
 - in platelets, 341
- mucosal bleeding, 15, 149
- multimerin, 62, 210
 - and platelet factor V, 85, 235
- multiple myeloma
 - and platelet function disorders, 85, 235
- Multiple Platelet Function Analyzer (Multiplate), 390
- Multiple Risk Factor Interventional Trial (MRFIT), 287
- multivesicular bodies
 - and formation of platelet α -granules, 2, 125
- mycophenylate mofetil
 - for refractory ITP, 29, 162
- myelodysplasia, 24, 39, 156, 167
- myelodysplastic syndrome, 53, 192
- myelogenous leukemia
 - acute
 - d-SPD and development, 60, 208
 - chronic
 - abnormal platelet function in, 84, 234
- myeloid progenitor, 5, 131
- myeloproliferative disorders, 2, 126
 - and platelet function disorders, 83, 233
- MYH9 gene, 108, 255
- MYH9-RD (myosin heavy chain 9 related disorders), 37, 166
- myocardial infarction, 3, 108, 127, 261
 - anticoagulants for preventing, 109, 265
 - risk in PAD patients, 458
- myosin light chain kinase, 43, 172

- myosin light chain phosphorylation
epinephrine and, 61
- nadroparin, 317
- Nak epitope on CD36, 29, 164
- Nak phenotype
racial difference, 30, 164
- NAP-2, 60, 207
- naproxen
and vascular events, 452
- National Cholesterol Education Project Adult Treatment
Panel III (NCEP ATP-III), 109, 263
- National Institute of Health (NIH) stroke scale, 447
- nematode anticoagulant peptide (NAPc2), 374
- neonatal thrombocytopenias
alloimmune (AIT), 43, 169–172
- neonatal thrombocytopenias, 41, 169
- neuronal NOS (nNOS), 96, 250
- neutropenia, 413
as antiplatelet therapy side effect, 380
from clopidogrel, 380
as ticlopidine side effect, 461
- neutrophil activating peptide-2 (NAP-2; CXCL-7),
108, 255
- neutrophil priming, 53, 191
- Newman, P.J., 27, 159
- Niemetz, J., 81, 230
- nitric oxide (NO; EDRF), 92, 95, 244, 250
bioavailability, 279
decreased availability of biologically active and PAD,
458
effect on platelet function, 96, 250
from endothelium, 109, 264
loss of function, 98, 252
- nitric oxide-donating aspirin (NO-aspirin), 351
- nitroaspirin, 463
- nocodazole, 9, 137
- noncompliance of patients, 392
- NSAID drugs, 115, 269
and COX-2 inhibitors, effect on stroke risk, 452
interaction with aspirin, 353
- NSTEMI, 367
- N-terminal side
of α IIb and β 3 chains, 25, 156
- nuclear factor kappa B (NF- κ B), and hyperglycemia, 285
- nucleoside triphosphate-diphosphohydrolases, 109, 265
- Nussmeier, N., 452
- O'Brien, J.R., 128
- OCS. *See also* open canalicular system (OCS)
- oculocutaneous albinism, 25, 208
- Ohmori, T., 355
- OM2, 351
- oncoproteins, 315
- open canalicular system (OCS), 1, 3, 124, 127
granule release of contents, 15, 149
- open heart surgery
therapeutic platelet transfusions in, 98, 252
- oral anticoagulants
vs. antiplatelet therapies
in atrial fibrillation, 376–378
for heart failure treatment, 376
bleeding with, 465
- orbofiban, 346
- organelles, 3, 11, 126, 139
mechanism of movement, 11, 139
- Organization to Assess Strategies for Ischemic Syndromes
(OASIS) pilot trial, 375
- orthopedic surgery
as risk factor for acute VTE, 473
warfarin vs. LMWH for VTE prophylaxis, 309
- osteoporosis
as corticosteroids side effect in children, 30, 164
- otamixaban, 371
- outpatients, prophylactic high-dose platelet transfusions for, 97,
251
- outside-in signaling, 46, 187
- oxidative stress, 99, 253
- ozagrel, 347
- P2T_{PLC} receptor, 343
- P2x₁ receptors
and responses to ADP, 45, 176
- P2Y₁ receptor abnormalities, 57, 204
- P2Y₁ receptors
and responses to ADP, 45, 176
- P2Y₁₂ inhibitor, 398
- P2Y₁₂ receptors, 343, 417, 473
abnormalities, 57, 204
inhibition and thienopyridine resistance, 396
and responses to ADP, 45, 175
- P2C1 receptor, 343
- paclitaxel-eluting stent, 417
- PAD. *See* peripheral artery disease (PAD)
- PAF. *See* platelet-activating factor (PAF)
- Paget-Schroetter syndrome, 9, 270
- palpable purpura, 15, 149
- pancytopenia
from clopidogrel, 380
in Fanconi's anemia, 106, 255
- paradoxical prothrombotic drug effects
and iatrogenic platelet disorders, 81, 230
- paraproteinemias, 85, 235
- parecoxib, 452
- Paris Trousseau Syndrome (PTS), 62, 108, 211, 255, 311
- Paris Trousseau Syndrome (PTS)
treatment, 316
- particulates
impact on cardiovascular morbidity and mortality, 63, 211
impact on platelet activation in animal studies, 67, 215
- pathogen reduction
for platelet transfusions, 87, 244
- pathological thrombi, 79, 228
- Patrono, C., 352
- PDGF. *See* platelet-derived growth factor (PDGF)
- PDHRF. *See* platelet derived histamine releasing factor (PDHRF)

Index

- PE. *See* pulmonary embolism (PE)
- PECAM-1, 324
- Pen/Yuk, 27, 159
- penicillins, bleeding and abnormal platelet function from, 82, 231
- pentasaccharides
antithrombotic therapy with, 370–372
- pentoxifylline, 463
- pepducin, 350
- percent platelet recovery (PPR), 93, 246
- percutaneous coronary intervention (PCI)
clopidogrel for, 415, 418
loading dose, 413, 416
GP IIb/IIIa inhibitors and, 419, 422
- percutaneous endovascular revascularization
antiplatelet therapies in, 465
- percutaneous transluminal angioplasty (PTA), 465
- pericytes, 315
- peridinin-chlorophyllprotein (PerCP), 8, 134
- peripheral artery disease (PAD), 287
atherosclerosis and, 279, 458
future research, 467
platelets' role in progression, 287
risk factors for, 458
- peripheral vascular disease, prostacyclin for, 349
- peripheral vascular surgery, vitamin K antagonists (VKA)
for, 464, 465
- peritoneal dialysis, 83, 232
- peroxisomes, 3, 126
- peroxynitrite, 99, 253
- perpetuation of platelet plug, 46–48, 190
other adhesion molecules, 47, 187
integrins, adhesion and outside-in signaling, 46, 187
ligand interactions at platelet
platelet interface, 47, 189
- petechiae in children
from ITP, 29, 163
- petechiae, 13, 147
- Peto, R., 438
- PFA. *See* platelet function analyzer (PFA)
- PFA-100, 3, 7, 128, 133
clinical utility, 7, 133
variable influencing, 7, 133
- pharmacodynamic resistance, 352
- pharmacokinetic resistance, 352
- phenprocoumon
and uncontrolled bleeding, 23, 152
- phosphatidylinositol 3-kinase (PI3K)
and Gas6 activities, 54, 194
- phosphatidylethanolamine, 83, 233
- phosphatidylinositol 4, 5-bisphosphate (PIP₂), 93, 246
- phosphatidylserine (PS), 66, 82, 213, 232
hypercoagulability and, 83, 232
in resting platelets, 108, 261
- phosphodiesterase (PDE), 348
- phosphodiesterase 3 (PDE₃)
cilostazol inhibition of, 116, 270
- phosphoinositide 3-kinase (PI3K), 61
- phosphoinositide hydrolysis
epinephrine and, 45, 186
- phosphoinositide in diabetic patients, 286
- phospholipase A₂ (PLA₂), 109, 264, 341
- phospholipase C (PLC), 39, 93, 167, 246, 341, 343
activation defects, 65, 213
activation of, 41, 168
- phospholipase C β (PLC β)
G_q and activation of, 41, 171
- phospholipid-rich surfaces
clotting complexes on, 84, 234
- phospholipids, 107, 255
in eukaryotic cells, 83, 232
impaired liberation of arachidonic acid from, 63, 212
- phycoerythrin (PE), 8, 134
- PI 3-kinases, 24, 43, 152, 172–175
- picotamide, 461
- plasma membrane
of platelet surface, 1, 124
- plasmapheresis, 27, 159
- plasminogen, 108, 261
 α granules release of, 93, 247
- plasminogen activator inhibitor (PAI-1), 112, 266
levels in diabetes mellitus-type II, 286
- platelet-activating factor (PAF), 109, 114, 264, 267, 327
experimental animal studies of intravenous administration, 329
- platelet activation, 37, 155–165, 341
and accelerated atherosclerosis, 293
and adhesion, 93, 246
as cause of mortality and morbidity, 341
consequences of uncontrolled, 69, 227
future research, 48, 191
gaps in signaling maps, 41, 168
mediators, 93, 246
preventing artefactual when drawing blood sample, 9, 137
rolling and, 294
soluble markers, 10, 139
b-thromboglobulin (β TG), 10, 139
glycoprotein (GP) V, 11, 139
platelet factor-4 (PF-4; CXCL-4), 10, 139
sP-selectin, 11, 139
in vivo, 39, 41, 167, 170
whole blood flow cytometric assays
benefits, 9, 138
- platelet adhesion
assay, 11, 140
evaluating under shear-induced flow conditions, 8, 134
shear conditions and, 341
- platelet aggregation
inhibitors, 472
of thrombin-induced, 349
with leukocytes, 159
- platelet aggregation primers, 53, 191
- platelet aggregation tests
agonist-induced, 5, 129
impedance (whole blood) platelet aggregometry, 6, 132
optical (turbidometric) platelet aggregometry, 4, 128

- platelet activation under controlled shear conditions, 7, 133
- platelet function under flow, 8, 134
- VerifyNow, 6, 132
- platelet aggregometry, 86, 236
 - advantage of, 4, 129
- platelet count
 - goal during surgery or trauma, 97, 251
 - normal range, 1, 125
 - post-transfusion, 93, 246
- platelet degranulation, 282
- platelet-derived endothelial cell growth factor (PD-ECGF), 315
- platelet-derived growth factor (PDGF), 109, 262, 315
 - platelet release of, 330
- platelet-derived histamine releasing factor (PDHRF), 326
- platelet-derived lipid mediators, 327
- platelet-derived microparticles (PMP)
 - and atherosclerosis, 284
- platelet endothelial cell adhesion molecule-1 (PECAM-1; CD31), 47, 98, 108, 187, 252, 261
- platelet–endothelial interaction, 94, 248
 - in inflammation, 95, 249
 - in thrombosis and hemostasis, 94, 248
- platelet “exhaustion,” 330
- platelet factor-4 (PF-4; CXCL-4), 108, 114, 255, 267, 296
 - measurement of plasma levels, 10, 139
 - and monocyte differentiation into macrophages, 298
- platelet function analyzer (PFA), 86, 236, 391, t394
 - limitations for screening, 69, 226
- platelet function disorders
 - absence of predictive screening test, 69, 226
 - acquired, 69, 225
 - β -lactam antibiotics, 82, 231
 - autoimmune platelet dysfunction, 85, 236
 - clinical aspects, 70
 - future research, 86, 237
 - von Willebrand syndrome, 85, 235
 - and blood diseases, 83, 233
 - leukemias, 84, 234
 - multiple myeloma, 85, 235
 - myeloproliferative disorders (MPD), 83, 233
 - correcting, 355
 - gene therapy, 355
 - disseminated intravascular coagulation, 83, 233
 - iatrogenic acquired, 82, 227–232
 - $\alpha_{IIb} \beta_3$ blockers, 80, 229
 - aspirin, 227
 - causes unrelated to drugs, 82, 231
 - paradoxical prothrombotic drug effects, 81, 230
 - thienopyridine, 79, 228
 - kidney disease and, 82, 232
 - from liver disease, 83, 232
 - surgical issues, 86, 236
- platelet function testing, 353, 386
 - bleeding time (BT) as, 386
 - flow cytometric analysis, 391
 - for monitoring antiplatelet therapy, 386
- Platelet GP IIb/IIIa in unstable angina
 - Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, 422
- Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON)-B trial, 423
- platelet inhibition
 - anti-inflammatory effects, 9, 270
 - ADP-receptor (P2Y₁₂) antagonists, 115, 269
 - COX inhibition and aspirin, 115, 268
 - GPIIb/IIIa receptor antagonists, 116, 269
 - phosphodiesterase inhibitors, 116, 270
- platelet–leukocyte aggregates
 - formation, 8, 135
- platelet plug formation
 - signaling initiated by epinephrine and stability, 66, 214
- platelet plug formation stages, 37–48, 190
 - extension, 25, 37, 166, 187
 - ADP, 43, 175
 - epinephrine, 45, 186
 - G protein-mediated signaling, 41, 167
 - G_q and activation of phospholipase C β , 41, 171
 - G_q G₁₃ and actin cytoskeleton, 43, 171
 - platelet activation in vivo, 41, 169
 - signaling through G_i family members, 43, 174
 - thrombin, 45, 176
 - thromboxane A₂ (TxA₂), 46, 186
 - initiation, 37, 39, 165, 166
 - perpetuation, 37, 46–48, 166, 190
 - other adhesion molecules, 47, 187
 - integrins
 - adhesion and outside-in signaling, 46, 187
 - ligand interactions at platelet
 - platelet interface, 47, 189
- platelet primers
 - classification, 227
- platelet priming. *See* priming
- platelet reactivity index (PR), 69, 227
- Platelet Receptor Inhibition for Ischaemic Syndrome Management (PRISM) trial, 368, 423
- Platelet Receptor Inhibition for Ischaemic Syndrome Management in Patients Limited to Unstable Signs and symptoms (PRISM- PLUS) trial, 368, 423
- platelet satellitism, 2, 125
- platelet transfusions. *See also* refractoriness to platelet transfusions
 - adverse reactions, 93, 246
 - available products, 86, 242
 - bacterial testing, 87, 243
 - extended stored platelets, 92, 244
 - gamma irradiation, 92, 244
 - leukoreduction, 86, 243
 - pathogen reduction, 82–87, 244
 - whole blood-derived platelet concentrates or apheresis
 - platelets, 86, 242
 - expected response
 - in adults, 93, 244
 - in infants, 93, 245
 - future research, 108, 255

Index

- platelet transfusions. (*Contd.*)
 for inherited platelet disorders, 68, 216
 mechanisms of poor responses, 93, 246
 molecular typing and compatible donor pool size, 94, 248
 prophylactic, 96, 250
 dose, 97, 250
 transfusion trigger, 97, 250
 therapeutic, 99, 251–254
- platelet-rich plasma (PRP) method of platelet preparation, 86, 242
- platelets
 cellular cross talk with endothelial cells and leukocytes, 106, 255
 coated, 86, 236
 correcting disorders of number
 thrombocytopenia. *See also* thrombocytopenia, 353
 thrombocytosis, 353
 function inhibition
 future research, 100, 254
 functions, 341
 main function of, 21, 150
 normal count, 1, 124
 physiological roles of, 341
 release in vivo, 11, 140
 requirements for, 37, 163–165
 size in ITP, 24, 156
See also activated platelets
- platelet-type bleeding disorder, 21, 150
- platelet-type von Willebrand disease (VWD), 55, 202
- Plateletworks, 227, 236
- ® aggregation kits, 390
- pluripotent stem cells
 megakaryocytes descendant from, 5, 131
- PMP. *See* platelet-derived microparticles (PMP)
- pneumococcaemia
 purpura fulminans and, 15, 149
- polyclonal antibodies (MoAbs)
 in whole blood flow cytometry, 137
- polycythemia vera (PV)
 VEGF and, 69, 226
- polymorphonuclear leukocytes
 in ischemic stroke, 288
- polyploidization
 in megakaryocyte regulation, 7, 132
- Post Coronary Artery Bypass Graft (Post CABG) trial, 375
- postsplenectomy thrombocytosis, 47, 187
- posttransfusion purpura
 Pen/Yuk and, 27, 160
- PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethylketone), 1, 124
- PPR (percent platelet recovery), 93, 246
- prasugrel, 344, 429, 473
 metabolism of, 344
- prednisone for ITP, 26, 158
 in children, 30, 164
- prekallikrein, 22, 151
- premature coronary artery disease
 and familial hypercholesterolemia (FH), 69, 216
- primary secretion defects, 58, 67, 204, 214
- primary thrombocytosis. *See* clonal thrombocytosis (CT)
- primers' effect in vitro
 cytokines, 25, 208
 chemokines, 59–60, 207
 leptin, 60, 208
 thrombopoietin (TPO), 58, 206
 vascular endothelial growth factor (VEGF), 58, 205
 foreign substances, 63, 211
 hormones, 61–62, 209
 epinephrine, 61, 209
 estrogens, 61, 209
 histamine, 61, 209
- ions
 zinc, 62, 210
- lipopolysaccharides (LPS), 63, 211
- prostaglandins, 62, 210
- proteins, 23, 205
 Factor VIII, 54, 194
 Gas6 (growth arrest-specific gene 6), 53, 193
 gelatinase A (MMP-2), 55, 202
 human fibroblast collagenase (MMP-1), 55, 202
 low-density lipoproteins (LDL), 57, 204
 matrix metalloproteinases (MMPs), 55, 201
 soluble CD40 ligand (sCD40L), 56, 204
 succinate, 64, 212
- primers' effect in vivo
 animal studies evidence, 64, 212
 cytokines, 65, 213
 Gas6 mice studies, 64, 212
 matrix metalloproteinases, 65, 212
 sCD40L, 65, 213
- human studies, 68, 215
 cytokines, 69, 226
 hormones, 69, 227
 prostaglandins, 69, 227
 proteins, 68, 215
- priming, 53, 191
- Pro219 allele, 30, 165
- procoagulant molecules, 108, 261
- progenitor cells
 platelet binding to, 300
- proinflammatory molecules
 activated platelet release, 107, 255
- promegakaryoblast, 6, 132
- promegakaryocyte, 6, 132
- prophylactic platelet transfusions, 96, 250
 dose, 97, 250
- proplatelets, 8, 134
 end amplification, 10, 139
 elongation
 polymerization and, 10, 138
 ends
 generation for platelet production, 11, 140
 formation dependence on microtubule function, 9, 137
 release, 11, 140
- prostacyclin, 12, 140
 for peripheral vascular disease, 349

- prostacyclin receptor (IP), 348
- prostaglandin H-synthase, 342
- prostaglandin pathway, 97, 250
- prostaglandins, 53, 92, 191, 244
- aspirin inhibition of production, 342
 - for critical limb ischemia, 463
 - effect on platelet function, 97, 251
 - human studies, 69, 227
 - mice studies
 - in vivo effect, 66, 214
 - platelet release of, 310
 - as primer, 62, 210
 - synthesis, 97, 250
 - stages, 342
- protease activated receptor (PAR) antagonists, 349
- protease-activated receptor family of G protein coupled receptors, 45, 186
- protease-activated receptors, 84, 234, 283, 430
- in tumor cell lines, 313
- proteases
- as platelet-derived mediators, 109, 264
- protein kinase C, 39, 167
- epinephrine and, 61, 209
- protein kinase C α (PKC α), 11, 139
- protein S, 108, 261
- proteins, 53, 191
- coating microtubules, 4, 128
 - deficiency in gray platelets in α granules, 62, 210
 - platelets ability to make, 299
 - as primers
 - Factor VIII, 54, 194
 - Gas6 (growth arrest-specific gene 6), 53, 192
 - gelatinase A (MMP-2), 55, 202
 - human fibroblast collagenase (MMP-1), 55, 202
 - human studies, 68, 215
 - low-density lipoproteins (LDL), 57, 204
 - matrix metalloproteinases (MMPs), 55, 201
 - soluble CD40 ligand (sCD40L), 56, 204
 - release identification from activated platelets, 106, 255
 - synthesis by platelets, 107, 255
- proteome
- characterization of cell's, 13, 141
- proteomics, 13, 48, 142, 190
- prothrombin G20210 A gene mutation, 310
- prothrombin time (PT), 21, 150
- prothrombinase
- impairment in δ -SPD platelets, 59–60, 208
- P-selectin, 2, 80, 125, 126, 229
- microvesicles and, 85, 234
 - MoAbs and, 9, 137
 - monocyte exposure to, 82, 231
- P-selectin (CD62P), 282, 324
- α granules release of, 93, 247
 - enhancement of monocyte adhesion to endothelial cells, 113, 261–267
 - and leukocyte tethering and rolling, 112, 267
 - and platelet rolling, 296
 - response to inflammatory stimuli, 95, 250
 - surface expression of, 108, 110, 261, 266
 - and tumor progression, 312
- P-selectin glycoprotein ligand-1 (PSGL-1), 351
- P-selectin/PSGL-1 axis, 81, 230
- pseudopodia, 9, 138
- pseudo-resistance, 395
- pseudothrombocytopenia, 2, 24, 125, 156
- from anticoagulants, 381
- pseudo-von Willebrand disease, 55, 202
- PSGL-1 (P-selectin glycoprotein ligand-1), 82, 112, 232, 267
- PSI-697, 351
- PT_{2AC} receptor, 343
- PTA (percutaneous transluminal angioplasty), 465
- pulmonary embolism (PE), 108, 261, 367, 471
- Pulmonary Embolism Prevention (PEP) trial, 271, 475
- pulmonary megakaryocytes, 12, 140
- purinergic receptors, 343
- in children
- purpura, 5–13, 147
- from ITP, 29, 163
 - posttransfusion
 - Pen/Yuk and, 27, 159
- purpura fulminans, 15, 149
- Quebec platelet disorder (QPD), 62, 210
- fibrinolytic inhibitor drugs for, 69, 216
- Quebec platelet syndrome, 85, 86, 235, 236
- quinidine
- and thrombocytopenia, 41, 168
- Qureshi, A., 447
- Rac family
- monomeric G proteins, 41, 168
- Raccuglia, G., 61–62, 209
- Radley, J.M., 8, 135
- Randomised Evaluation in PCI Linking Bivalirudin to Reduced Clinical Events (REPLACE)-2 trial, 427
- Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trial, 422
- RANTES (Regulated on activation normal T cell expressed and secreted), 60, 112, 207, 267, 296, 298
- and inflammation, 326
 - and leukocyte activation, 114, 267
 - PMPs as transfer system for, 284
- Rao, A.K., 65, 213
- rapid platelet function assay, 4, 128
- Ratnoff method, 3, 127
- reactive oxygen species (ROS), 99, 253
- in hypertensive patients, 99, 254
- reactive thrombocytosis (RT)
- vs. clonal, 53, 191
 - conditions associated with, 45, 46, 186
- receptors
- for Gas6, 53, 193
 - on platelet surface, 38, 166
 - in platelets, 21, 150
- recombinant FVIIa, 69, 216
- recombinant hirudin, 372

Index

- recombinant t-PA
 - for ischemic stroke treatment, 288
- refractoriness to platelet transfusions, 93, 246
 - alloimmunized, 93, 247
 - management, 94, 248
 - prevention, 93, 247
 - management strategies for persistent, 96, 250
 - nonimmune, 95, 248
- renal failure
 - and elevated plasma levels of β -TG, 11, 139
- reocclusion after angioplasty
 - abciximab to reduce rate, 466
- resistance, 392
 - to antiplatelet agents, pharmacogenomic factors, 353
 - clinical, 352
 - meaning of term, 351
 - pharmacodynamic, 352
 - pharmacokinetic, 352
 - pharmacologist's definition, 352
- RESISTOR trial (Research Evaluation to Study Individuals who show thromboxane or P2Y12 Resistance), 398
- respiratory disorders, 329–332
 - asthma, 159
 - clinical studies, 330
 - experimental animal studies, 329
 - chronic obstructive pulmonary disease (COPD), 332
 - cystic fibrosis, 332
- resting platelets
 - $\alpha_{IIb}\beta_3$ in, 26, 157
 - filaments of, 4, 129
 - intracellular components, 1, 124
 - actin cytoskeleton, 4, 128
 - cytoskeleton, 3, 127
 - granules, 1, 124
 - marginal band of microtubules, 3, 128
 - membrane systems, 3, 127
 - organells, 3, 126
 - spectrin membrane skeleton, 5, 129
 - phosphatidyl serine (PS) in, 108, 261
 - structure, 1–5, 131
- retention test Homberg, 69, 227
- reteplase, 428
- reversible platelet aggregation, 5, 130
- reviparin, 370, 475
- rheumatoid arthritis, 334
- Rho family
 - low molecular weight GTP-binding proteins in, 43, 172
 - monomeric G proteins, 41, 168
- riboflavin
 - adding to platelet transfusions, 92, 244
- Ridker, P., 438
- ridogrel, 348
- rifampin
 - impact on clopidogrel, 353
- ristocetin
 - and platelet aggregation, 5, 131
 - response to, 60, 207
- rituximab
 - for ITP, 27, 160
 - side effects, 27, 161
- rivaroxaban
 - for venous thromboembolism prevention, 373
- Rocca, B., 352
- rofecoxib, 452
- rolling, 296
 - P-selectin and, 294
- Roncaglioni, M.C., 408
- Rotational TEG, 391
- RT. *See* reactive thrombocytosis (RT)
- Rumpel-Leede test, 14, 148
- S18886, 348
- Sanofi's anti-thrombotic discovery programme, 343
- sarrogelate, 463
- sCD40L. *See* soluble CD40 ligand (sCD40L)
- SCH 530348, 430
- Schulman, S., 317
- Scott syndrome, 66, 83, 84, 213, 233, 234
- scramblase enzyme, 83, 233
- scramblases, 108, 261
- screening programs
 - for AIT, 43, 172–175
 - antenatal management, 43, 172
 - management, 43, 172
- SCUBE1 protein, 299
- SDF-1 α , 59, 207
- Sebastian Syndrome, 108, 255
- Second Northwick Park Heart Study, 317
- second-hand smoke and atherosclerosis, 109, 264
- secretogranin III, 13, 142
- selectin, 324
 - and platelet-EC adhesion, 110, 265
- selective serotonin reuptake inhibitors (SSRI's), 351
- sepsis
 - bacterial
 - from contamination of platelet transfusions, 87, 243
 - as splenectomy risk, 27, 161
- Ser/Pro substitution, 30, 165
- serotonin
 - δ granule storage of, 325
 - dense granules release, 93, 247
 - in dense granules, 2, 126
 - and platelet activation, 93, 245
 - platelet receptors for, 341
 - platelet release of, 310
 - platelet storage of, 60, 207
- serotonylation, 86, 242
- Sevitt, S., 472
- SFLLRN (thrombin receptor-activating peptide), 5, 131
- shape of platelets, 1, 124
 - change, 14, 41, 93, 147, 169, 246
- shear conditions
 - platelet activation under controlled, 7, 133
 - and platelet behavior, 388

- shed blood vs. venous blood
 platelet number and MMP-2 content, 68, 216
- shiga-like toxin, 45, 176
- Sib alloantigen, 24, 155
- sibrafiban, 346
- sickle cell anemia, 82, 231
- signaling
 cascade triggered by leptin, 60, 208
- signaling pathways
 identification of, 302
- signal-transduction pathways abnormalities, 63, 212
 arachidonic acid (AA) impaired liberation from membrane phospholipids, 63, 212
 cyclooxygenase defects, 64, 212
 GTP-binding proteins abnormalities, 64, 212
 phospholipase C activation defects, 65, 213
 thromboxane synthetase, 64, 212
- sildenafil, 81, 231, 349
- simian immunodeficiency virus, 357
- sirolimus-eluting stents, 417
- Sistrurus miliaris barbouri*, 346
- Sit alloantigen, 29, 163
- skeletal abnormalities
 in Fanconi's anemia, 106, 255
- skin template bleeding time, 3, 127
- Sky receptor
 for Gas6, 53, 193
- SLAM (signaling lymphocytic activation molecule; CD150), 47, 189
- SLE. *See* systemic lupus erythematosus (SLE)
- SMAD proteins, 13, 147
- smoking, and cardiovascular disease, 109, 264
- sn-1, 2*-diacylglycerol (DAG), 93, 246
- sodium citrate, 1, 124
- Solomon, S., 452
- soluble CD40 ligand (sCD40L)
 in ischemic cardiovascular disorders, 68, 216
 as platelet primer, 56, 204
 mouse studies, 65, 213
- soluble CD40L, 82, 231
- soluble platelet activation markers
 glycoprotein V (GPV), 11, 139
 granular contents, 10, 139
 platelet adhesion assay, 11, 140
 sP-selectin, 11, 139
- Spanish National Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF), 377
- spectrin membrane skeleton, 5, 129
- Speroff, T., 475
- sphingosine 1-phosphate (S1P), 315
- spices, and platelet function in vitro, 82, 231
- spleen, platelets pooled in, 92, 244
- splenectomy
 bacterial sepsis as risk, 27, 161
 failures, 9, 161
 for ITP treatment, 27, 159
 for ITP treatment
 in children, 30, 165
 decision to defer, 11, 161
 thrombocytosis after, 46, 187
- splenectomy
 and improved platelet increments, 95, 249
- sP-selectin, 11, 139
- SSR126517 (biotinylated idraparinux), 371
- statins, and abnormal platelet function testing, 82, 231
- steel factor, 13, 141
- ST-elevation MI (STEMI)
 clopidogrel for patients with, 417
 GP IIb/IIIa inhibitors in patients with, 428–429
- stem cell factor, 13, 141
- Stent Anticoagulation Restenosis Study (STARS) trial, 413
- stent implantation
 aspirin with thienopyridine for, 415
 carotid, abciximab for, 447
 clopidogrel
 pretreatment and duration of treatment, 416
 vs. ticlopidine, 419
 treatment duration after, 416
 combination clopidogrel/aspirin therapy after, 444
 ticlopidine after, 445
- stent thrombosis
 cilostazol with aspirin and clopidogrel to prevent, 349
 prevention of, 413
- storage temperature
 and platelet function, 1, 124
- stress fibers, 324
- stress platelets, 2, 126
- stroke, 108, 261, 288
 anticoagulant role in preventing, in atrial fibrillation, 376
 antiplatelet therapies in prevention, 438
 aspirin and reduction of, 377
 COX-2 inhibitors and NSAIDs impact on risk, 452
 etiologies and antiplatelet agents' role, 437
 hemorrhagic, 437
 prevention of secondary
 IIb/IIIa inhibitor for, 447
 recurrence rates, 451
 risk in PAD patients, 458
 source of, 437
 warfarin and reduction of, 377
 warfarin for prevention, 449
- Stroke Prevention in Atrial Fibrillation (SPAF) study, 377
- Stroke Prevention in Atrial Fibrillation I (SPAF-1) trial, 439
- Stroke Prevention in Atrial Fibrillation-III (SPAF III) trial, 451
- Stroke Prevention using an Oral Thrombin Inhibitor in atrial Fibrillation (SPORTIF) studies, 452
- Stromorken syndrome, 66, 214
- Study of Platelet Inhibition and Patient Outcomes (PLATO), 429
- subendothelial matrix
 platelet adhesion to, 23, 152
- succinate
 as primer, 64, 212
- succinic acid, 64, 212
- superoxide, 99, 253
- surface of the platelet plasma membrane, 1, 124

Index

- surgical procedure
platelet count goal in, 97, 251
survivin, 7, 133
Swedish Aspirin Low-Dose Trial (SALT), 440
systemic lupus erythematosus (SLE)
and ITP, 29, 163
systolic dysfunction
anticoagulation for, 115, 269
- T/C polymorphism, 30, 165
tachycardia
and need for fluid replacement, 13, 147
tacrolimus
impact on platelet transfusion outcome, 95, 250
telmisartan, 303
tenase
extrinsic and intrinsic, 83, 232
tenecteplase (TNK), 428
terbogrel, 348
TF. *See* tissue factor
TF/VIIa complex
and coagulation, 83, 232
TGF- β . *See* transforming growth factor- β (TGF- β)
TGF β 1, 13, 147
therapeutic platelet transfusions, 99, 251–254
Thiagarajan, P., 3, 127
thienopyridine effect, 69, 227
thienopyridines, 371, 372, 473.
antiplatelet effects, 412
for arterial thrombosis treatment and prevention, 110, 265
with aspirin, for peripheral endovascular procedures, 466
and iatrogenic platelet disorders, 79, 228
mechanism of action, 344
for peripheral arterial disease, 460
resistance, 396
See also clopidogrel; ticlopidine
Thiery, J.B., 8, 134
thrombotic disorders
sP-selectin as marker, 11, 140
Thr/Met substitution, 24, 155
thrombin, 45, 176, 308, 349, 367
binding by, 84, 234
role in cancer, 313
formation, 283
GPIb/IX/V as high-affinity binding site for, 23, 152
GPV levels and, 11, 139
impact on tumor dormancy, 317
inhibitors of, 350
and initiation of platelet activation, 37, 166
platelet activation by
whole blood measurement, 9, 138
and platelet activation in vivo, 39, 166
platelet receptors for, 341
platelet response to, 45, 186
production by coagulation system, 79, 228
unfractionated heparin (UFH) and, 367
thrombin activatable fibrinolysis inhibitor (TAFI),
83, 232
thrombin-induced platelet aggregation, inhibitors of,
349
thrombin-receptor activating peptide (TRAP), 10, 84, 138, 234
thrombin-receptor antagonists
future research, 430
thrombocytopenia 125
and bleeding, 53, 191
clinical manifestations, 47, 189
drug induced, 167
from heparin, 168
epidemiology, 47, 189
essential (ET), 45, 47, 186, 187
and bleeding, 48, 191
clinical manifestations, 47, 189
epidemiology, 47, 189
future research, 54, 176, 194
inherited, 41, 165–167
children with, 29, 163
myelodysplasia, 39, 167
neonatal, 41, 169
pathogenetic mechanisms, 46–48, 190
prognosis, 53, 193
treatment, 54, 194
thrombocytopenia, 2, 23–24, 125, 155, 309, 353
congenital, management, 108, 255
dilutional, trauma and, 98, 252
from drugs, 21, 150
in gray platelet syndrome, 62, 210
in infants, 106, 255
congenital, 100, 254
X-linked congenital, 107, 255
macothrombocytopenias, 107, 255
and petechiae, 14, 148
as ticlopidine side effect, 461
See also alloimmune thrombocytopenia (AIT); immune
thrombocytopenic purpura (ITP)
Thrombocytopenia and Absent Radius (TAR) syndrome,
29, 61, 163, 209
thrombocytosis, 353
in cancer patients, 311
causes of, 45, 186
threshold platelet count, 45, 186
thromboelastograph platelet mapping system,
69, 227
thromboelastography (TEG), 86, 236, 391, 395
thromboembolism
arachidonic acid-induced platelet, 67, 214
high FVIII levels and, 54, 201
Thrombolysis in Myocardial Infarction (TIMI) 8 trial, 372
Thrombolysis In Myocardial Infarction (TIMI) study
group, 378
thrombolytic agents
administration, 23, 152
thrombomodulin, 109, 265
thrombopoiesis
rate of, 2, 126
role for proplatelet formation, 8, 135
thrombopoietin as regulator, 13, 141

- thrombopoietin, 8, 13, 135, 141, 354
 in vivo effect mice studies, 65, 213
 levels in ITP, 26, 157
- thrombopoietin (TPO)
 as primer, 58, 206
 human studies, 69, 226
 and reactive thrombocytosis, 25, 187
- thrombopoietin (Tpo) receptor
 and variation in normal platelet counts, 45, 186
- thromboprophylaxis
 antiplatelet agents effect on, 309
 aspirin role in, 310
- thrombosis
 abdominal vein (AVT), 47, 190
 managing ET-associated, 54, 194
 risk factors in ET, 53, 193
- thrombosis. *See also* arterial thrombosis
 $\alpha_{IIb}\beta_3$ role in, 25, 156
 arterial
 leptin and, 66, 213
 blood-borne TF role in, 81, 229
 and cancer, 227
 historical perspective, 311
 laboratory findings in hypercoagulation, 311
 platelet role in metastasis, 312
 thrombin role, 313
 tissue factor role, 313
 tumor cell adhesion, 312
- chamber-based
 clinical presentation, 113, 267
 risk factors for, 114, 267
 treatment and prevention, 115, 269
- clinical approach, 108, 261
 future research, 272
 high-shear vs. low-shear, 108, 261
 platelet-endothelial interaction in, 94, 248
 PMPs and, 284
- Thrombosis Prevention Trial (TPT), 374, 408
- thrombospondin
 α granules release of, 93, 247
 surface level of, 86, 242
 and tumor cell adhesion, 313
- Thrombostat 4000, 391
- thrombotic thrombocytopenic purpura (TTP), 37, 43, 70, 165, 175, 227
 as antiplatelet therapy side effect, 380
 ticlopidine and risk of, 445
 from ticlopidine, 413
- thromboxane, 97, 251
 measuring levels for monitoring aspirin, 396
 platelet release of, 310
- thromboxane A2 (TxA2), 37, 46, 166, 186
 abnormal generation in ET, 48, 191
 and allergic inflammation, 327
 aspirin and decrease in, 472
 aspirin effect and, 411
 aspirin inhibition of, 79, 227
 defects, 23, 205
 measurement of, 391
 and platelet activation, 93, 107, 245, 255
 platelet receptors for, 341
- thromboxane B₂ (TxB₂), 12, 140
 in VTE, 472
- thromboxane pathway inhibitors, 347
- thromboxane synthetase
 defects, 64, 212
- thrombus
 formation of pathological, 21, 150
 formation, 367
- thromboembolic disorders
 urinary thromboxane B₂ (TxB₂) for diagnosing, 12, 140
- thymus and activation-regulated chemokine (TARC; CCL17), 59, 108, 255
- ticlopidine, 79, 115, 228, 269, 343, 413, 473
 vs. clopidogrel for stent placement, 419
 lack of recommendation, 464
 and need for vascular surgery, 463
 PAD patients in trials using, 461
 side effects, 380
- tifacogin, 374
- tirofiban, 81, 229, 346, 368, 392, 419
 vs. abciximab, 422
 for arterial thrombosis treatment and prevention, 112, 266
 bleeding complications, 379
 for cerebrovascular disease, 444
 dosing regimen, 422
 pharmacokinetics, 419
 thrombocytopenia from, 380
- tissue factor (TF), 86, 242
 role of arterial wall, 81, 229
 blood-borne, 80, 229
 and coagulation cascade, 283
 platelet products enhancing synthesis, 79, 228
 platelet products increasing production, 81, 230
 platelet substances for stimulating synthesis, 82, 231
 platelet synthesis, 299
 tumor cells and, 313
- tissue factor pathway inhibitor (TFPI), 374
- tissue inhibitors of metalloproteinases (TIMPs), 55, 202
- tissue regeneration, platelets and, 316
- toll-like receptors (TLRs), 324
- toll-like-receptor-4 (TLR4), 63, 211
 mice studies, 67, 215
- total body irradiation (TBI), impact on platelet transfusion outcome, 95, 250
- TPO. *See* thrombopoietin (TPO)
- TRA-418, 348
- transcription factor N κ B, 82, 231
- transcriptome
 for platelets, 48, 190
- transforming growth factor- α (TGF- α), 109, 262
- transforming growth factor- β (TGF- β), 109, 262, 315
 platelet release of, 330
- transfusion-related acute lung injury (TRALI), 86, 242

Index

- transfusions of platelets, 27, 159
 - for AIT
 - intrauterine, 43, 173
 - in neonates, 43, 175
- transient ischemic attack (TIA), 108, 261, 288
- transient megakaryocytic leukemia, 41, 169
- TRAP. *See* thrombin-receptor activating peptide (TRAP)
- trauma
 - platelet count goal after, 97, 251
 - therapeutic platelet transfusions for, 97, 251
- Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction (TACTICS-TIMI) 18 trial, 425
- TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), 429
- Trial To Reduce Alloimmunization to Platelets (TRAP Trial), 93, 248
- Triatoma infestans*, 351
- triflusal, 377
- triplatins, 351
- tropomodulins, 5, 129
- troponin elevation, 423
- Trousseau, A., 311
- tubular membranes, 8, 134
- tubulin, 9, 136
- tumor necrosis factor (TNF) superfamily, 56, 203
- tumor necrosis factor- α (TNF- α), 25, 187
 - CD40L and, 114, 267
- Turpie, A., 452
- Twist gene, 313
- TxA₂. *See* thromboxane A₂ (TxA₂)
- TxA₂ metabolites, 12, 140
 - aspirin inhibition of, 407
- type IV collagen
 - and tumor cell adhesion, 313
- tyrosine kinase receptors, 53, 193
- tyrosine phosphorylation, 60, 208

- U46619, 5, 131
- ulcerative colitis, 333
- Ultegra rapid platelet function analyzer, 6, 132, 390
 - See also* VerifyNow
- unfractionated heparin (UFH)
 - for anticoagulation, 367
- United Kingdom-TIA (UK-TIA) trial, 441
- unstable angina (UA), 367
- uranaffin reaction
 - in δ -granules, 59, 207
- urban pollution
 - impact on cardiovascular morbidity and mortality, 63, 211
- uremia
 - in HUS, 45, 176
 - platelet dysfunction and, 22, 232
- uremic thrombocytopeny, 83, 232

- urinary markers
 - TxA₂ metabolites, 12, 140
 - TxB₂, 12, 140
- US Physicians' Health Study, 463
- Ushikubi, F., 58, 205
- UV-A light
 - platelet exposure to, 92, 244

- vaccines
 - in ITP treatment in children, 31, 165
- valdecoxib, 452
- valsartan, 303
- valvulopathy, thromboembolism from, 114, 115, 267, 268
- Vane, J., 342
- Varon, D., 390
- vascular damage
 - platelet response to, 13, 147
- vascular disease, 3, 99, 126, 251–254
- vascular endothelial growth factor (VEGF)
 - platelet release of, 313, 330
 - as primer, 58, 205
 - human studies, 69, 225
- vascular endothelium
 - as antithrombotic surface, 97, 251
 - dysfunction, 93, 244
 - and cardiac disease, 98, 252
 - in vascular disease, 98, 252
 - normal function, 92, 244
 - substances impacting platelets
 - ecto-ATPDase, 97, 251
 - nitric oxide (NO), 95, 250
 - prostaglandins, 97, 250
 - surface-bound antiplatelet factors, 98, 252
 - PECAM-1, 98, 252
 - thromboregulatory systems of, 92, 244
- vascular injury
 - thrombin generation at, 39, 166
- vascular surgery, 463
- vasodilator-stimulated phosphoprotein (VASP), 97, 251
- VASP assay, 397
- VCF. *See* velocardiocardial syndrome (VCF)
- velocardiocardial syndrome (VCF), 37, 166
- veno-occlusive disease of the liver (VOD)
 - impact on platelet transfusion outcome, 95, 250
- venous thromboembolism
 - antiplatelet therapies for, 471
 - orthopedic surgery as risk factor, 473
 - platelet aggregation inhibition, 472
 - platelets in pathogenesis, 471
 - preventing
 - air travel-related, 478
 - future research, 479
 - in high-risk patients, 473
 - recurrent, 478
 - risk factors for, 471
 - rivaroxaban for preventing, 373
- venous thrombosis, 108, 261
 - clinical presentation, 116, 270

- consequences of, 108, 261
 future research, 318
 platelets role in, 280, 308
 prevention and treatment, 270
 risk factors for, 107, 270
 VerifyNow, 5, 70, 132, 227, 390, 393, 395, 397
 Aspirin assay, 79, 228
 VerifyNow Aspirin cartridge, 395
 VERITAS (The Verify Thrombosis Risk Assessment) trial, 397
 vero toxin, 45, 176
 Verona Diabetes Study, 287
 vessel wall-derived substances, 92, 244
 vincristine, 9, 138
 Virchow's triad, 108, 116, 261, 270, 471
 vitamin C deficiency (scurvy)
 and ecchymoses, 14, 148
 Vitamin E, in cystic fibrosis, 332
 vitamin K, 22–23, 152
 vitamin K antagonists (VKA), 373
 for arterial thrombosis treatment and prevention, 112, 267
 to prevent recurrent VTE, 478
 for thromboprophylaxis, 471
 for vascular graft patients, 464, 465
 and VTE risk reduction, 479
 vitronectin, 345
 and tumor cell adhesion, 313
 vitronectin receptor, 345
 von den Borne, A.E., 27, 160
 von Willebrand disease (VWD), 55, 67, 126,
 202, 215
 aspirin impact, 128
 PFA-100 for screening, 7, 133
 testing for, 69, 226
 type IIB, 39, 166
 von Willebrand factor (VWF), 108, 255, 282, 308
 α granules release of, 93, 247
 $\alpha_{IIb}\beta_3$ integrin as receptor, 24, 156
 binding to GPIb/IX/V, 23, 152
 GPIb/IX/V as adhesive receptor for, 21, 150
 levels in diabetes mellitus-type II, 286
 MMP-2 and, 56, 203
 multimers, 37, 165
 in multivesicular bodies, 2, 126
 receptor, 3, 127
 surface level of, 86, 237
 von Willebrand factor cleaving protease, 45, 175
 von Willebrand syndrome
 acquired (AVWS), 53, 191
 bleeding in MPD and, 83, 233
 and platelet function disorders, 85, 235
 walking distance
 impaired arterial circulation and, 463
 warfarin, 115, 269, 373
 and antiplatelet therapy, 374
 with aspirin, 374
 for PAD, 461
 for preventing stroke, 452
 for atrial fibrillation, or aspirin, vs., placebo, 450
 compared with clopidogrel and aspirin, 418
 vs. LMWH, for prophylaxis of VTE, 309
 reduction of strokes, 377
 for stroke treatment and secondary prevention, 448
 and uncontrolled bleeding, 23, 152
 Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial, 376
 Warfarin and Aspirin for Symptomatic Intracranial arterial stenosis (WASID) trial, 449
 Warfarin and Aspirin for the prevention of Recurrent iSchemic Stroke (WARSS) trial, 448
 Warfarin/Aspirin Study in Heart Failure (WASH) study, 376
 Warfarin-Aspirin Re-Infarction Study-2 (WARIS-2) trial, 375
 WARIS (Warfarin Aspirin Reinfarction Study), 112, 267
 Weibel-Palade bodies, 95, 250, 296
 Weiss, H.J., 59–60, 67, 208, 214
 Wells criteria, 9, 270
 White platelet syndrome (WPS), 63, 211
 whole blood aggregometry (WBA), 388
 Wholey, M., 447
 willow bark, 342
 Wiskott–Aldrich syndrome, 2, 29, 39, 61, 126, 163, 166, 209
 in infants, 107, 255
 Women's Health Study, 408
 Wang, R., 27, 160
 wound healing, platelets and, 316
 Wright, James Homer, 7, 133
 Wu, K.K., 67, 127, 214
 xemilofiban, 346
 ximelagatran, 350, 373
 X-linked coagulation disorder, 15, 150
 X-linked congenital thrombocytopenias in infants, 107,
 255
 X-linked thrombocytopenia
 with thalassemia (XLTT), 62, 210
 X-linked thrombocytopenia (XLT), 39, 166
 Y-20811 inhibitor, 347
 Yusuf, S., 375
 Zacharski, L., 316
 zinc
 as primer, 62, 210
 zinc binding motif (HEXXHXXGXXH), 55, 202
 zymogen factor X, 83, 232
 zyxin
 zinc and, 63, 211